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Estradiol has primarily been associated with the female reproductive system; however, 
estradiol receptors have been located in the retinas of male and female humans, as well as 
throughout the central nervous system (CNS) including lower brainstem areas associated 
with oculomotor functioning. The present study investigated the significance of estradiol 
in relation to smooth pursuit eye movements (SPEM) with the specific intention of 
localizing estradiol effects on realtime and on extrapolated SPEM tracking after target 
termination. This was accomplished in two ways.  First, testing occurred at two opposing 
stages of the female menstrual cycle: the late follicular and the late luteal phases, where 
estradiol levels are known to be high and low respectively. Second, we selected 
participants symptomatically categorized into three groups: women who did not have 
Premenstrual Syndrome (PMS)-type symptoms and who were not using hormonal 
contraception within the last three months (control group), women who were hormonally 
sensitive due to the presence of PMS-type symptoms and were not using hormonal 
contraception (PMS-type group), and women who were using the hormonal contraceptive 
Alesse™ or the generic form Aviane™ (Alesse™ user group).  
Horizontal SPEMs were measured using a 60 Hz infrared eye tracker. We found 
deviations from nominal sinusoidal eye movement patterns between our control, PMS-
type and Alesse™ user groups in which the hormonally sensitive and regulated groups 
(PMS-type and Alesse™ users) showed shorter durations of persistence (defined as 
duration of movement that statistically followed an extrapolated track after target 
termination), greater amplitude excursions, and a left-to-right excursion bias.  These 
findings suggest that further efforts should be made in order to better understand the 
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modulatory interactions of stable estradiol- or low progesterone-based affective 
symptoms and their underlying common neural circuitry with SPEM maintenance. The 
relevant SPEM neural circuitry includes the cerebellar vermis and flocculus, the medial 
vestibular nucleus, and other areas where estradiol has been reported to exert its effects.  
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The Effect of Cycling Female Estradiol Levels on Retinal-Based Smooth Pursuit 
Eye Movement Persistence 
 
Estradiol receptors are located throughout the mammalian central nervous system 
(Kaja, Yang, Wei et al., 2003; McEwen & Milner, 2007) and they have been located in 
the retinas of both male and female humans (Munaut, Lambert, Noel, Frankenne & 
Deprez, 2001; Ogueta, Schwartz, Yamashita et al., 1999; Wickham, Gao, Toda et al., 
2000). Retinal signals can be processed through a number of pathway circuits including 
oculomotor systems involved with smooth pursuit eye movements (SPEM) and higher 
end cortical systems such as those devoted to image formation.  Therefore, it is logical to 
assume that cycling estradiol concentration levels and/or the degree to which one is 
hormonally sensitive to changing hormone levels across the menstrual cycle may have an 
influential role on a number of vision-based systems. Further, the presence of estradiol 
receptors in the cerebellum (Andreescu et al., 2007) and in the lower brainstem (Medina 
& Lisberger, 2007; Raffi, Squatrito, & Maioli, 2007; Schlack, Hoffmann, & Bremmer, 
2003; Sparks, 2002) may demonstrate estradiol modulatory influences on cerebellar-
based eye movement patterns. 
Estradiol and Visual Perceptual Functioning 
In the last decade, changes in the female sex steroid estradiol have been found to be 
associated with changes in visual perceptual functioning, particularly with regards to 
short-wavelength light processing. For example, Eisner, Burke, and Toomey (2004) 
demonstrated that short-wavelength sensitive cone (S-cone) sensitivity might be related 
to estradiol changes during the menstrual cycle. Two groups of women were tested: one 
group containing four women not on oral contraceptives or any other medicinal hormonal 
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substitute, and the other made up of three women using the oral contraceptive Ortho Tri-
Cyclen™. One participant belonged to both groups at two different times. In this study, 
participants were tested five days a week using a psychophysical method that collected 
threshold versus illuminance (tvi) data. A tvi function plots difference thresholds as a 
function of adapting field illuminance and chromaticity. Tvi effects were assessed with 
background illuminances ranging from 1.2 log troland (td) to 4.4 log td in 0.4 log td unit 
steps.  Test wavelengths of 440-, 460-, 490-, 510-, 580-, and 640- nm were also used. Of 
the seven participants, one showed evidence of visual sensitivity changes that occurred 
around day 14 of her menstrual cycle.  This was in line with her time of ovulation.  Of 
particular interest was the fact that this participant fully participated in both the control 
and the experimental test groups due to her starting time on an Othro Tri Cyclen™ 
regimen midway through the study.  In this case, the S-cone based tvi curves were found 
to be steeper during the late luteal (LL) phase than during the late follicular (LF) phase 
especially for the 440-nm tests on 4.0 log td backgrounds. Thus, her S-cone mediated 
vision was most sensitive during the LF phase, and these changes were detected prior to 
her use of oral contraceptives, (i.e., changes were not detected when the oral 
contraceptive use was initiated).  Seeing as the significant results were found prior to 
contraceptive use, and due to the fact that non-contraceptive users should show greater 
estradiol cyclicity, this, and other studies detailed below, supports the theory that 
naturally cycling estradiol alters visual functioning.  It is important to note that these 
findings reflect the results of one participant; therefore, this study required replication in 
order to garner more confidence in the findings. 
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Several other studies have examined wavelength sensitivity with hormone 
medications (see Eisner et al., 2004; Eisner, O’Malley, Incognito & Toomey, 2006; 
Eisner, Toomey, Incognito, O’Malley & Samples, 2006).  One of the main focuses of 
these studies has been the selective-estrogen-receptor-modulator (SERM) tamoxifen, 
which is used to treat women with breast cancer. SERMs are compounds that have 
similar effects to receptor agonists and antagonists, however SERMs have differing 
effects on estrogen receptors depending on where the tissue is located.  For example, 
Tamoxifen acts as an agonist at bone and as an antongist at breast and uterus.  Tamoxifen 
has been found to affect colour discrimination while apparently not affecting the general 
integrity of the lens, cornea, or macula (Gorin, Day, Costantino, Fisher & Redmond, 
1998). Eisner et al. (2004) demonstrated that tamoxifen affects S-cone mediated visual 
sensitivity, likely because of the localized presence of estradiol receptors in the retina. 
The reason S-cones were examined over the other photoreceptors is because of their 
susceptibility to environmental toxins and other exogenous agents (e.g., Haug, Kolle, 
Trenkwalder, Oertel, & Paulus, 1995; Heron, Adams, & Husted, 1988; Pacheco & Edgar, 
1999). Eisner, Austin, and Samples (2004) used the Short-Wavelength Automated 
Perimetry (SWAP) test to assess S-cone sensitivities with SERM use.  The SWAP 
measures S-cone retinal sensitivity across four concentric rings at 3°, 9°, 15°, and 21° 
eccentricity, in which short-wavelength “blue” spots of light superimposed on a bright 
middle wavelength “yellow” background are presented along different spatial positions 
within each of the rings.  
Eisner et al. (2004) showed that the duration of tamoxifen use (in years) was 
negatively correlated with S-cone mediated visual sensitivity.  That is, there was less 
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retinal S-cone sensitivity with the use of the SERM compared to non-tamoxifen users. 
Interestingly, SWAP sensitivities were most dependent on treatment duration when 
examining the visual field periphery (>21°).  In other words, those participants who had 
lower levels of sensitivity to the peripheral stimuli often had a history of using tamoxifen 
for longer periods of time.  The fact that differences in S-cone sensitivity are putatively 
dependent on duration of tamoxifen use exemplifies the potential importance of retinal 
estradiol on S-cone specific functionality.  We argue that if duration of tamoxifen use can 
have this effect on retinal sensitivity, then naturally occurring changes in estradiol levels 
associated with the female reproductive cycle may also have an effect. In fact, Gupta, 
Johar, Napgal and Vasavada (2005) observed, through in situ hybridization, retinal 
estrogen receptor mRNA. This implicates the retina as a potential primary target for 
endogenous estradiol modulation.  As gonadotropins fluctuate during different phases of 
the reproductive cycle, the retinally-based estrogen receptors may be affected as much as 
other, more traditional receptor sites, and consequently visual sensitivity changes 
comparable to those indirectly observed with the tamoxifen studies may result. 
Ultimately, retinal sensitivity may be increased during the late follicular phase of the 
menstrual cycle when there are heightened levels of estradiol present.  
The Oculomotor System Overview  
Several oculomotor systems enable the primate visual system to have high foveal 
acuity even when an image is in motion. Such systems include optokinetic movement, 
vergence, vestibular ocular movement, saccadic movement, and SPEM (e.g., Krauzlis, R. 
J., 2005; Ono & Mustari, 2008; Sharpe, 2008).  The last two systems are prominent as 
compensatory mechanisms for restricted spatial resolution and kinetic image change.  
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Due to the fact that the number of axons in the optic nerve is limited, the visual system 
has relatively high spatial resolution representation located in a very small area of the 
fovea.  Thus, the nervous system has to adapt to this spatially restricted area with fast 
acting saccadic precision and foveal-tracking SPEM. 
SPEM facilitates volitional eye movements that allow for the close examination of 
an image located on or near the fovea (i.e., the central retina that falls in line with the 0° 
visual axis and is responsible for central visual acuity necessary for detail-demanding 
activities such as reading or driving). Several cortical regions known as the cortical 
pursuit system, support SPEM.  These regions are interconnected and include the middle 
temporal (MT), frontal eye field (FEF), lateral intraparietal, supplementary eye fields 
(SEFs), and medial superior temporal (MST) cortex (Ilg & Their, 2008; Ono & Mustari, 
2008).  Evidently, the cortical pursuit system is intricately separated into subdivisions, 
with each subdivision being responsible for different aspects of SPEM signal processing.  
For example, the MT region is involved in detecting retinal-based motion signals and 
serves as a closed-loop signal necessary for SPEM execution (Ilg & Their, 2008). 
The other type of eye movement that compensates for spatial resolution is the 
saccadic system, which is a two-step process that begins with a high velocity gaze shift 
shadowed by visual fixation. Although saccades are useful for initially establishing image 
fixation on the fovea, SPEMs are necessary for stabilizing foveated retinal images of 
moving objects (Ono & Mustari, 2008).  Essentially, saccades are used to place the 
desired image on the fovea, and SPEM is used to keep the moving image stable on the 
fovea.  Although SPEM and saccades are functionally disparate, their coordination is 
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suggestive of a neural link across pathways (Ilg & Thier, 2008; Missal et al. 2002; Sharpe, 
2008).  
A substantial amount of research has been done on the brain regions involved with 
SPEM and saccadic eye movements in rhesus monkeys (Macaca mulatta) because of the 
many similarities found between humans and macaques. Methods of studying smooth 
pursuit in the macaque typically include micro-stimulation and lesion work in order to 
locate areas of the brain that are involved in processing SPEM information, such as the 
junction of parietal, temporal and occipital cortex at area V5, and their respective 
connections with the parietal and FEFs. Projections from these areas are then sent to the 
brainstem and the cerebellum (Krauzlis, 2005; Sharpe, 2008).  Of most interest to the 
present study are the projections to the cerebellum and brainstem regions of the cerebrum 
including nuclei in the following areas: paramedian pontine reticular formation, rostral 
interstitial nucleus of the medial longitudinal fasciculus, and the central mesencephalic 
reticular formation.  The ventral paraflocculus and lobules VI and VII of the vermis are 
the cerebellar regions that are involved in SPEM, and they project to the vestibular nuclei, 
which then connect to ocular motor nuclei in the brainstem (for a review, see Sharpe, 
2008). Portions of the SPEM pathways that will be referred to in this study are 
schematically outlined in Figure 5. 
Studies have shown that inhibition plays a key role in SPEM.  For example, there 
are omnipause neurons in the pons that are responsible for inhibiting excitatory burst 
neurons known to elicit saccades (Krauzlis, 2005; Missel & Kellar, 2002; Sharpe, 2008).  
Omnipause neurons, therefore, are involved in controlling the temporal course of pursuit 
by inhibiting saccades.  The GABAergic system is a key inhibitory transmitter system in 
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the CNS (e.g., Rewal, Jung, Brun-Zinkernagel, & Simpkins, 2003; for a review, see 
Walker, 1983).  In addition to the above, it is also important to note that estradiol has 
been found to inhibit GABAergic systems (e.g., Hu, Watson, Kennedy, & Becker, 2006; 
Noriega et al. 2010; Velisek & Veliskova, 2002; Wagner, Ronnekleiv, Bosch, & Martin, 
2001). One notable recent study revealed that estradiol deprivation results in enhanced 
GABA receptor activity in the arcuate nucleus (Daendee, Thongson, & Kalandakanond-
Thongsong, 2013).  Consequently, SPEM, by virtue of its dependence on active 
inhibition by the omnipause neurons to the excitatory burst neurons, may be a behavioral 
expression that is influenced by cycling estradiol during the menstrual cycle.  These 
points will be further discussed in the following section.  
The transduction of the target movement/image motion to the retinal image is what 
elicits SPEM responses.  Deviations in eye velocity from the target velocity are corrected 
for by retinal slip signals that become active when these deviations are detected (Krauzlis 
& Lisberger, 1989).  Retinal slip signals activate what is referred to as “the controller” 
(Krauzlis & Lisberger, 1989; Lisberger, Morris, & Tychsen, 1987). The controller works 
on error signals derived from comparisons between kinesthetic gaze movement (the sum 
of eyeball and head movements) and target movement in space (retinal image movement) 
(Krauzlis & Lisberger, 1989; Lisberger, Morris, & Tychsen, 1987). The initiation of 
SPEM in the natural environment lags actual target movement by about 100 ms, mainly 
due to visual system delays (Sharpe, 2008). However, if target movement is anticipated, 
then the pursuit delay is reduced or even eliminated (Jarret & Barnes, 2002).  In our study, 
we plan to focus on predictive horizontal SPEM because primates, including humans, 
perform better at eye tracking tests that include a horizontally moving stimulus rather 
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than a vertical one, and also because there is less noise associated with a horizontally 
moving stimulus due to the lessening of catch-up saccades required of this directional 
track (Rottach et al., 1996).  
Estradiol and Oculomotor Activity  
As noted above, not only does estradiol putatively affect cone sensitivities, but it 
also can influence oculomotor activity (e.g., Andreescu et al., 2007; Gyenes, Hoyk, 
Csakvari, Siklos, & Parducz, 2010). Oculomotor dysfunction has been related to 
Premenstrual Syndrome (PMS), a condition in which symptoms increase during the late 
luteal phase of the menstrual cycle and include depressed mood, anxiety, irritability, 
affective lability, difficulty concentrating, changes in appetite, low energy, decreased 
interest in usual activities, changes in sleep, headaches, a sense of being overwhelmed or 
out of control, breast tenderness or swelling, abdominal bloating, and joint or muscle pain 
(Pearlstein & Steiner, 2007). Interestingly, individuals with PMS-type symptoms 
demonstrate an increased likelihood to engage in a phenomenon referred to as the 
attention-startle-response (Kaviani, Gray, Checkley, Raven, Wilson & Kumari. 2004).  
The attention-startle-response is an involuntary response to fixate on a newly presented 
stimulus.  The fact that PMS-type individuals have a propensity for startle further 
highlights the possible connection between oculomotor functioning and estradiol. 
Because of the unique hormonal dynamics that are characteristic of PMS, as well as the 
presence of estradiol receptors throughout the rhombencephalon, it may be that the 
oculomotor substrates that mediate automated reflexive startle response effects are 
modulated by the same unique hormonal patterns that are present in women with PMS. 
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In addition to the attention-startle-response, mood disorders such as clinical and 
seasonal depression have also been shown to alter oculomotor behaviors such as saccadic 
movement, electrooculographys (EOGs) and SPEM (e.g., Flechtner, Steinacher, Sauer, & 
Mackert, 1997; Kathmann, Hochrein, Uwer, & Bondy, 2003; Lam, Beattie, Buchanan, 
Remick, & Zis, 1991; Mahlberg, Steinacher, Mackert, & Flechtner, 2001; Ozaki, 
Rosenthal, Myers, Schwartz, & Oren, 1995; Pardo, Pardo, Humes, & M, 2006; Seggie, et 
al.,1991; Wichniak, Riemann, Kiemen, Voderholzer, & Jernajczyk, 2000).   
Pardo et al. (2006) used a task developed by Posner et al. (1984) referred to as the 
“Posner Task” to assess visuospatial attention in depressed patients.  They used nine 
participants who were clinically depressed and who were not receiving any treatment, 
and fourteen non-depressed participants.  The Posner Task involved the participant sitting 
in front of a video monitor where they were told to fixate on a mark in the center of the 
screen.  The participants were instructed to press a key as quickly as possible with their 
index finger when the target (an asterisk) was presented in the center of either the left or 
right visual field target region.  Participants were cued as to the location of the target on 
some of the trials with the use of the previous target becoming brighter 1 s following the 
beginning of the trial.  The probability of the subsequent target being presented in that 
same brightened region was 80%.  The target was presented either 100 or 800 ms after 
the onset of the cue (stimulus onset asynchrony—SOA). Depressed patients performed 
significantly slower compared to the controls for all of the conditions demonstrating that 
patients with depression experienced attentional deficits during relatively complex tasks, 
which in this case caused them to experience psychomotor slowing.  Pardo et al.’s 
depressive psychomotor slowing phenomenon may also be evident in SPEM persistence. 
Running head: SPEM AND ESTRADIOL 
 
17 
SPEM persistence is the continuation of tracking following stimulus or target offset. 
SPEM is volitional which inherently requires attention; therefore SPEM persistence 
probably reflects a vulnerability to attentional deficits like those expressed by depressed 
participants. 
Wichniak et al. (2000) investigated eye movement properties using 21 randomly 
selected polysomnograms collected from patients with major depressive disorders.  The 
polysomnograms were collected from two consecutive nights in a sleep laboratory.  
Rapid eye movement (REM) latency (LREM), REM density (RD), latencies of eye 
movement (LEM), and mean latency of eye movements (M-LEM) were measured.  The 
depressed participants demonstrated higher RD, shortened M-LEM and shortened LEM 
in the 1st and 4th REM sleep periods.  Again, these findings suggest that depression 
affects oculomotor functioning, with eye movement latency being related to depression. 
Due to the fact that mood alteration is also a symptomatic expression of PMS, it is logical 
to hypothesize that the modulated oculomotor pathways associated with mood disorders 
have convergent pathways in individuals with PMS. 
As previously mentioned, SPEM persistence is a visual phenomenon in which 
tracked SPEMs continue to be elicited following the termination of a repetitiously 
moving target.  The persistence of an eye-movement is an example of an automatic 
learned motoric pattern that is controlled by the cerebellum and other lower brain stem 
regions where estradiol receptors have been found (Andreescu et al. 2007; Kawakami & 
Ohno, 1981; Robinson & Fuchs, 2001).  The present study investigated the significance 
of estradiol in relation to oculomotor functioning with the specific intention of localizing 
potential SPEM pathways involved with tracking persistence. In order to isolate the role 
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of estradiol, testing was done across three groups of participants during two opposing 
stages of the female menstrual cycle: the late follicular (LF) and the late luteal (LL) 
phases, where estradiol levels are known to be high and low respectively. A control 
group, consisting of women who have not been using hormonal contraception for at least 
three months and who were not categorized as PMS-type, was included as a means to 
assess the cyclicity of estradiol throughout the menstrual cycle compared to women who 
were categorized into the PMS-type or Alesse™ user group; both of which were 
expected to demonstrate estradiol stability throughout the menstrual cycle.  It is 
important to note that including the PMS-type group was not an effort to better 
understand these symptoms or treat them. There is evidence that women with PMS-type 
symptoms experience estradiol stability across the menstrual cycle (Wesner & Richards, 
2011; Wesner, Currie, Richards & Oinonen, 2014).  Therefore, including the latter group 
as well as monophasic oral contraceptive users in this study allowed us to compare 
naturally cycling estradiol to stabilized estradiol, as Alesse™ users take a standard dose 
of 20 µg of ethinyl estradiol and 0.10 mg of progestin levonorgestrel daily for the 
duration of the 28 pill package. We expected to see changes in estradiol and progesterone 
across the menstrual cycle that is in agreement with Table 1 (see page 57). 
Menstrual Cycle Overview 
The first day of the menstrual cycle is marked by the first day of menstruation.  At 
this time, estrogen and progesterone levels are low, and gonoadotropin-releasing 
hormone (GnRH) is secreted from the hypothalamus.  The secretion of GnRH stimulates 
the release of Follicle Stimulating Hormone (FSH) from the pituitary.  This marks the 
beginning of the follicular phase.  The secretion of estrogen from the ovarian follicles is 
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stimulated by the release of FSH, which results in the cellular proliferation of the uterine 
lining. Negative feedback is exerted by estrogen on FSH release from the pituitary and 
one follicle becomes dominant and secretes increasing amounts of estrogen.  This marks 
the middle follicular phase as well as the end of the first week of the menstrual cycle.  
The second week of the menstrual cycle involves an increase in the pulsatile release of 
GnRH leading to the secretion of the luteinizing hormone (LH).  This is the beginning of 
the luteinizing phase.  The secretion of LH triggers ovulation (the expulsion of the egg 
from the follicle).  Ovulation coincides with a rising surge of estrogen levels, and 
ovulation represents the end of the follicular phase (Parry et al., 2006).  Post ovulation, 
the corpus luteum releases large amounts of progesterone, as well subtle amounts of 
estrogen compared to progesterone.  If the egg is not fertilized atrophy of the corpus 
luteum occurs.  Here, progesterone levels decline and the initiation of menstruation takes 
place in which shedding of the uterine lining occurs within 12-16 days of ovulation (Reed, 
Levin, & Evans, 2008).  There are declining estradiol levels during the last few days of 
the luteal phase of the menstrual cycle which signals a release of the negative feedback 
on the FSH secretion, and a rise in FSH levels leads to the next menstrual cycle (see 
Figure 1).  
Horizontal SPEM Neural Circuitry 
Research on the neural circuitry involved in horizontal SPEM is a relatively 
burgeoning area, however the recent focus on this subject has pointed to several brain 
regions of importance to this study.  Although intricate, the neural circuitry involved in 
horizontal SPEM has been isolated in several areas of the brain.  The projection pathways 
involved in horizontal SPEM include the medial superior temporal (MST), middle 
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temporal (MT), and the frontal eye fields (FEF) to ipsilateral pontine nuclei to 
contralateral cerebellar (dorsal) vermis (lobules VI and VII) then through vestibular and 
abducens cranial nuclei (Fukushima, 2003; Sharpe, 2008).  Sharpe (2008) discovered that 
lobule IX of the cerebellar vermis is involved in regulating bidirectional lowering of 
horizontal pursuit gain.  Another finding involves the neural integrator circuit that 
regulates horizontal SPEM.  This circuit is made up of the nucleus prepositus hypoglossi 
(NPH) and the middle vestibular nucleus (MVN).  Together, the NPH and the MVN 
transform eye-velocity signals to eye position signals in order to integrate conjugate eye 
movements (Sharpe, 2008).  Lastly, second order vestibular neurons excite lateral rectus 
motorneurons and rectus internuclear neurons in the contralateral abuducens nucleus to 
produce smooth eye motion.  This pathway creates a double decussation of the horizontal 
pursuit pathway wherein the first decussation occurs at the ponto-cerebellar projections 
through contralateral middle peduncle to vermis and paraflocculus and the second 
decussation is from the second order vestibular neurons in the MVN to the contralateral 
abducens (Sharpe, 2008). Again, pathways that are the focus of this study are outlined in 
Figure 5. 
Horizontal SPEM Neural Circuitry and Estradiol 
 Cerebellum and brainstem. Several connections can be made between estradiol 
receptor activity and the rhombencephalon.  For example, the floccular lobe of the 
cerebellum is involved in automated horizontal SPEM.  Horizontal P-Cells found in the 
floccular lobe seem to play a role in SPEM maintenance because they discharge after 
SPEM onset (Fukushima, 2003).  Fukushima notes that lesions to the floccular lobe and 
the dorsal vermis (lobues VI and VII) reduce SPEM amplitude change and that 
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Horizontal P-cells from the floccular lobe send projections to the brainstem, an area 
noted for its involvement in SPEM.  According to Sharpe (2008), the cerebellum is 
responsible for executing motor commands that are involved in SPEM and the flocullus 
and the dorsal parafloculus are involved in amplitude change.  
 There are functional differences that should be noted regarding the flocullar lobe 
and the dorsal vermis. Firstly, the floccular lobe controls slow eye movements, whereas 
the dorsal vermis controls eye velocity in conjunction with eye and head movements 
(Fukishima, 2003). A notable finding by Andreescu et al. (2007) and colleagues is that 
estradiol receptors are present in the cerebellum (specifically the vermis and floccular 
lobe) and that estradiol has been shown to affect motoric learning.  Given that estradiol 
has been shown to exert its effects in the cerebellum with respect to motoric learning, it is 
likely that estradiol may also play a role in the SPEM properties that are regulated by the 
cerebellum.  Further, elevated levels of aromatase have been found in the cerebellum.  
Aromatase is an important metabolic enzyme in that catalyzes the last step in 
biosynthesis of estrogen.  In a study by Biegon et al. (2010) Positron Emission 
Tomography (PET) scans revealed that estradiol regulates neurogenesis in Purkinje cells 
and interneurons in the cerebellum. Other evidence that implicates the role of estradiol in 
SPEM functioning comes from Tsutsi (2012) who noted several morphological changes 
in the cerebellum based on estradiol levels.  He found that estradiol deficiency in mice 
decreases dendritic growth, spinogenesis, and synaptogenesis in Purkinje cells.  All of 
this evidence is suggestive that fluctuations in estradiol levels (such as the respective 
peak-to-trough changes in estradiol during the menstrual cycle) may affect SPEM in the 
cerebellum. 
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Although there are several areas of the brainstem that are known to be tuned to 
SPEM including the dorsolateral pontine nuclei (DLPN) and the nucleus reticularis 
tegmenti pontis (NRTP), experimental research that demonstrates the impact of estradiol 
levels in the brainstem have focused primarily on one brain area: the MVN (Sharpe, 
2008) (See Fig. 4). The MVN is involved in integrating conjugate eye movements. In a 
study by Scarduzio et al. (2013) they tested the impact of estradiol on mice MVN.  When 
E2 is blocked in mice they found that long-term potentiation (LTP) of the neurons in the 
MVN was abolished while the opposing long-term depression systems went unaffected.  
Also, when E2 is present, the MVN is more active.  By virtue of the increased activity of 
the MVN, the integration of conjugate eye movements should be enhanced; perhaps 
leading to greater amplitude gain at peaked levels of estradiol such as during the LF 
phase of the menstrual cycle. 
Estradiol and Brain Plasticity 
The effect of estradiol on memory, through neuroplasticity and mechanisms of 
synaptic enhancement, is an area that needs to be further examined, especially with 
respect to the cerebellum.  Andreescu et al. (2007) posit that, like the hippocampus (see 
Scarduzio et al 2013; Shiroma, Yamaguchi, & Kometani, 2004; Vouimba, Foy, Foy, & 
Thompson, 2000), there is a strong presence of estradiol receptors in the cerebellum.  
Therefore, it is not unreasonable to predict that similar, albeit less pronounced, estradiol-
based morphological changes related to learning and memory detected in the 
hippocampus may also occur in the cerebellum (Hedges, Ebner, Meisel, & Mermelstein, 
2012; Rhodes & Frye, 2004). In fact, Andreescu and colleagues were interested in motor 
memory formation, and expected to see motoric behavioural changes correlate with 
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physiological cerebellar changes that relate to changes in estradiol levels during the 
reproductive cycle.  Specifically, based on the morphological impact of E2 on 
hippocampal memory formation, Andreescu and colleagues speculated what impact 
estradiol would have on the plasticity of the vestibulo-ocular reflex (VOR) following a 
visuovestibular training paradigm that included the pairing of head rotation with 50 
minutes of rotation of the visual environment. The type of plasticity that Andreescu and 
colleagues investigated was long-term depression (LTD) and long-term potentiation 
(LTP), molecular events that were studied at the parallel-fiber to Purkinje-cell synapse. 
Interestingly, LTP has been found to have a negative effect on neural gain in the 
hippocampus, whereas LTD has a positive effect (Cordoba & Carrier, 1997; Hansel, 
Linden, & D’Angelo, 2001). The authors focused on cerebellar LTP because it has been 
shown to decrease VOR gain which is defined as the change in eye angle divided by the 
change in the head angle during a head turn (Boyden & Raymond, 2003).  Horizontal and 
vertical VOR gain should be about 1.0—anything different and image motion on the 
retina potentially causes blurred vision.  More accurate eye movements can be achieved 
with motor learning to adjust for VOR gain.  
The cerebellum is vital to motor learning, and given estradiol presence in the 
cerebellum, estradiol may mitigate LTP in the cerebellum (similar to what happens in the 
hippocampus) ultimately enhancing cerebellar plasticity. The Andreescu (2007) study 
was designed to investigate the effects of E2 on LTP at the parallel fiber to Purkinje cell 
synapse on gain-decrease training of the VOR. The researchers predicted that estradiol 
modulation of LTP would decrease VOR gain, which would correct retinal image motion 
and enhance motor learning. Seventy, 6 to 8 week old female C57BL/6 mice, 17 male 
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C57BL/6 mice, and 8 Purkinje cell-specific ER- β knock-out female mice were subjected 
to the tests. Mice, like humans, are mammals and, therefore, share many similarities in 
structure and function throughout the CNS making most results found in rodent research  
potentially generalizable to the human population. In one group of female mice (Eovx 
mice), E2 was at a constant high level caused by ovariectomy (OVX) as well as daily 
subcutaneous injections of 5 µg of estradiol benzoate dissolved in 0.1 ml sesame oil.  In 
the other group (Covx mice), E2 levels were stabilized at low levels by OVX with 
subsequent daily subcutaneous injections of only 0.1 ml of sesame oil.  Intact female and 
male mice were used as controls. Daily vaginal smears were taken, as well as blood and 
uterus collections on the day of testing to ensure correct hormonal status. The mice 
received daily treatments of estradiol or saline between days 0 and 28 and were kept in 
complete darkness between the training (days 19-20) and testing (days 26-27) days.  
VOR measurements were taken pre-and-post training using a visual-vestibular interactive 
training paradigm that consisted of the presentation of phase sinusoidal vestibular and 
visual stimuli (±5°, 0.2-1 Hz).   
Post-mortem sagittal slices were collected from the cerebellar vermis of the Eovx, 
Covx and the two groups of control mice. The slices were stored in artificial CSF and 
whole-cell patch-clamp recordings were performed at room temperature. The presynaptic 
and postsynaptic levels of LTP and LTD were estimated by measuring a paired-pulse 
facilitation (PPF) ratio, which is found by stimulating the parallel fibers with two pulses 
delivered 50 ms apart, and examining the voltage-clamp recording responses.  The 
second pulse has a corresponding facilitated response because of short-term enhancement 
in synaptic efficacy that is caused by residual presynaptic Ca2+, permitting more 
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transmitter release.  Parallel fibers were investigated alone in order to assess LTP, and 
LTD was examined according to the stimulation of the parallel fibers being affected by 
other fibers. Again, it was essential to differentiate LTP from LTD so that the effects of 
VOR gain (as a means to stabilize images on the retina) via LTP could be assessed in 
order to determine whether estradiol affected VOR gain in the cerebellum.  LTP was 
hypothesized to decrease VOR gain and enhance motor learning, whereas LTD was 
predicted to increase VOR gain. 
The flocculus (from OVX females that received the daily estradiol benzoate 
injections) was processed for electronic microscopy in order to determine the synaptic 
density at the parallel fiber and climbing fiber to Purkinje cell. The number of synapses 
was counted from each brain and the total postsynaptic density area (PSD) and the PSD 
perimeter were measured. 
The results showed that when LTP was induced in the Eovx mice, the excitatory 
postsynaptic current (EPSC) amplitude was higher compared to the Covx mice.  These 
findings were replicated when comparisons were made between the Eovx mice and the 
male control group. There were no significant findings for LTD.  Estradiol did, however, 
improve VOR motor learning as defined by VOR gain decreases assessed by before and 
after visuovestibular training. The Eovx mice showed a 60% decrease in VOR gain 
whereas the Covx mice had a significantly smaller learning effect. These motor learning 
advantages were attributed to the initiation of LTP at the parallel fiber to Purkinje cell 
synapse.  Further, the post-mortem analyses of the flocculus showed that ERß was 
localized in the cell soma and dendrites in the Purkinje cells in both the flocculus and 
paraflocculus along with their terminals and in the vestibular nuclei.  This study confirms 
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the existence of estradiol receptors in the cerebellum and that estradiol can affects 
motoric learning via the vermis and the flocculus in the cerebellum.  The Andreescu et al. 
study also sheds lights not only on the effects of estradiol on the EPSC during motoric 
learning, but also on sexually dimorphic traits that may be implicated by estradiol. The 
observed sexually dimorphic disparity  (Eovx group compared to the male mice) on the 
visuovestibular task performance could be related to cerebellar motor learning that 
affects the proestrus needs of females to find and attract an appropriate male.  Such a 
finding may explain other sexually dimorphic traits in humans where females out-
perform males, including verbal ability and fine motor skills (Epting & Overman, 1998). 
Another interesting theory relating visuovestibular control regulation by estradiol 
involves pregnancy.  Like the estrous cycle, changing estradiol levels during pregnancy 
may influence the Purkinje cell activation in the cerebellum.  Andreescu et al. (2007) 
suggest that during pregnancy, changes in abdominal size inevitably changes the center 
of gravity leading to distorted balance.  This makes it necessary for the 
vestibulocerebellum to reset for balance maintenance. If the VOR has to adjust for a new 
center of gravity, then enhancement related to estradiol may speed up the motor learning 
required of such an adjustment.  Therefore, estradiol may play an influential role in 
ensuring that postural balance is maintained and eye movement position is not interrupted, 
potentially leading to parturition success. 
In a related way, estradiol has also been found to play a role in spatial reference 
memory (important for navigation), various forms of visual memory, as well as problem 
solving controlled by the cerebral cortex (Frick et al., 2002; Leuner et al., 2004) all of 
which implicate hippocampal-type plasticity with coordinated oculomotor spatial activity.  
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While estradiol's primary role may be predominately reproductive in nature, it appears 
that it also plays other homeostatic roles through the modulations of cerebellar, cerebral 
brainstem and associative cortical neural circuits related to oculomotor activity. 
Estradiol, PMS/PMDD, and Eye Movement Effects 
According to the Diagnostic and Statistical Manual of Mental Disorders (5th ed.; 
DSM-V; American Psychiatric Association, 2013), severe PMS, known as Premenstrual 
Dysphoric Disorder (PMDD), is operationalized as having mood-related symptoms 
experienced prior to menses. Some of these symptoms include: depressed mood, anxiety, 
irritability, affective lability, difficulty concentrating, changes in appetite, low energy, 
decreased interest in usual activities, changes in sleep, headaches, a sense of being 
overwhelmed or out of control, breast tenderness or swelling, abdominal bloating, and 
joint or muscle pain (Pearlstein & Steiner, 2007). In order to be diagnosed with PMDD, 
the luteal phase must be associated with the experience of impairment of social and/or 
work functioning caused by the premenstrual symptoms.  Interestingly, this hormonal 
disorder PMDD has also been found to affect eye movements (Nyberg et al., 2004).  
Nyberg et al. (2004) conducted a study that measured eye movements in women 
with PMDD who were subjected to alcohol infusions during the laboratory sessions.  
Time of testing occurred in the mid follicular and late follicular phases. Fourteen women 
who met the criteria for PMDD participated in the study, and 12 women without 
significant dysphoric symptoms participated as part of the control group. The participants 
were tested on four occasions, twice during each testing phase.  Within each menstrual 
cycle phase participants from both groups were randomly selected to receive a low dose 
of alcohol or a placebo infusion within an interval of 48 hours. Baseline levels of 
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estradiol and progesterone plasma were taken with the use of an intraveneous cannula 
inserted in each forearm.  The researchers also took three sets of saccadic eye velocity 
(SEV) measurements and visual analogue ratings to determine the participants’ baseline 
SEV. EOG was used to measure SEV. The stimuli included an array of light-emitting 
diodes (LED) at eye level, 67 cm from the glabella.  Subjects were instructed to focus on 
the LED and then move their eyes to the subsequent LED displays following the offset of 
the previous LED.  Apparent target movements as induced by the phi phenomenon 
occurred at 1.5-sec intervals.  A fixed, non-random sequence of 4 x 20 targets producing 
target steps of 10°, 20°, 30°, and 40°, was displayed.  The EOG was DC amplified and 
low–pass filtered.  The 80 individual EOGS were analyzed by processing the data from 
each target displacement to locate the saccades.  The saccades were analyzed to 
determine the saccade in degrees, the peak saccadic acceleration, deceleration, and 
latency from target movement to onset of saccade.  A velocity-saccade size curve was 
used to process the saccadic parameters.  The results showed that PMDD participants that 
received the low dose of alcohol had reduced SEV and saccade deceleration during the 
late luteal phase compared to the mid-follicular phase. While under the alcohol condition 
the control group did not show a significant change in SEV or saccade deceleration.  The 
authors concluded that women with PMDD were more susceptible to changes in eye 
movements, specifically SEV, compared to the control group when they were exposed to 
low doses of alcohol. It is interesting to note that alcohol is known to interact with 
several neurotransmitter systems, particularly GABAergic and serotonergic, two systems 
that interact with estradiol (Rapkin, 1999). The latter study provides indirect evidence 
that differences in estradiol activity between women with PMDD and control women 
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may have an effect on saccadic eye movement properties.  Given that saccadic and 
SPEM are two eye movements that work in opposition to one another, one might expect 
similar findings from the latter study to be found with respect to SPEM in women with 
PMDD versus controls.  
Altered levels of progesterone is a factor related to PMS-type symptoms.  
Progesterone is produced by the corpus luteum, which is also involved in implementing 
the cyclicity of PMDD.  This is important to note because, although the present study 
focuses on the effects of estradiol on SPEM functioning due to the presence of estradiol 
receptors in the retina and throughout the CNS, progesterone is likely to have indirect 
effects on SPEM by virtue of its antagonistic interaction with estradiol throughout the 
menstrual cycle.  Reduced sensitivity to GABAergic substances have been found in 
PMDD patients during the late luteal phase (Sunstrom et al., 1998).  Once again, the 
cyclicity of PMDD is implemented by the corpus luteum, and progesterone is the major 
steroid that is produced by it.  This is important because endogenous progesterone 
metabolites, called neurosteroids, are involved in the allosteric modification of GABAA-
receptors increasing receptor affinity (Majewska, Harrison, Schwartz, Barker, & Paul, 
1986). Thus, progesterone modulation may lead to GABAergic system enhancement of 
inhibition.  If the production of progesterone is affected by the corpus luteums interaction 
with PMDD, and if the exocytotic release of GABA is affected by progesterone, which 
by its very nature is interactive with estradiol levels, then it is reasonable to hypothesize 
that other areas that are driven by GABA may be affected by the inhibitory-implications 
caused by PMDD, such as SPEM. In fact, the GABA agonist muscimol has been shown 
to cause reduced velocity of saccades via the superior colliculus (Hikosaka & Wurtz, 
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1985).  Therefore, PMDD may have indirect implications for eye movements via the 
GABAergic system -- possibly through the omnipause system that inhibits excitatory 
burst neurons known to elicit saccades.  Again, while estradiol is known to inhibit GABA, 
progesterone is antagonistic to estradiol throughout the menstrual cycle, therefore 
progesterone may enhance the inhibition of omnipause neurons ultimately inhibiting 
saccades via excitatory burst neurons.  
Also related to the latter, some studies have shown that individuals with PMS-type 
symptoms have slowed psychomotoric responses. For example, Kaviani et al. (2004) 
conducted a study that demonstrates that participants with Major Depressive Disorder 
(MDD) display what is known as the attention-startle-response in response to 
emotionally positive, neutral and negative short films.  The attention-startle-response, as 
pointed out earlier, occurs when an involuntary reaction is made to a precipitous sensory 
stimulus onset. Such psychomotoric slowing was previously found with respect to 
affective limbic responses (Kaviani et al., 2004) and oculomotor fixation (Donaghy et al., 
2009). Given that many behaviours that are regulated by various and diffuse areas of the 
CNS are affected by the attention-startle-response, it is not surprising that Kaviani and 
colleagues investigated the effects of the later phenomenon on oculomotor behaviour in 
order to see if visual cues have implications for oculomotor reactivity.  Kaviani and 
colleagues used a 50 dB white burst-tone as their startle stimulus. The startle stimulus 
was presented three times during each of the 6 short films.  Startle amplitude, baseline 
electromagnography (EMG), latency to response onset, and affective responses were 
included as the dependent variables.  The results showed a main effect of valence in 
which systematic increases in startle amplitude were found with increases in 
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unpleasantness. Therefore, all of the participants displayed more intense startle responses 
to the unpleasant clips.  However, a significant main effect for group was found wherein 
the highly depressed group showed slower startle reflexes relative to the low depressed 
group and the control group.  Participants with affective disorder-symptoms have more 
difficulty dissociating from the invoking stimulus compared to a low depression group 
and control participants. In other words, Kaviani et al. showed that MDD individuals 
took longer to redirect the gaze off of a precipitous stimulus onset.  
Evidently, the hormonal implications for affective disorders such as depression, 
PMS and PMDD are related to eye movements insofar as women with PMS-type 
symptoms may have difficulty dissociating from visual stimuli. Therefore, SPEMs and 
SPEM persistence, in which eye tracking continues even after termination or offset of a 
target stimulus, may also be affected by this psychomotor slowing, and this slowing may 
be partially attributed to GABAergic modulation mentioned above. 
Finally, dysregulated eye movements have been related to PMDD, depression, and 
sleep, and these oculomotor dysregulations have also been linked to estrogen. For 
example, Hadjimarkou, Benham, Schwarz, Holder, and Mong (2008) investigated 
estradiol influences on sleep physiology by measuring electroencephalograhic recordings 
on gonadally intact and ovariectomized female rats.  The researchers discovered that 
rapid eye movement sleep phases (REM) were blunted when estradiol levels peaked in 
the intact mice compared to the other days of the estrous cycle. Also, the amount of sleep 
activity that occurred in the intact mice was reduced during the times of peaked estradiol 
compared to when there was minimal estradiol in the cycle. These changes related to eye 
movements, estradiol, and sleep were not found in the ovariectomized rats, and as such, 
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these findings suggest that estradiol has a regulatory effect on sleep.  This result is 
especially interesting with respect to REM in that REM is defined by prominent 
oculomotor activity; again, supporting the hypothesis that estradiol may play a role in the 
control of eye movements. 
In a polysomnography experiment (a multi-parametric sleep test) Shechter, 
Lesperance, Kin, and Boivin (2012) examined the sleep patterns of PMDD and non-
PMDD control women.  In this study, women spent every third night of their menstrual 
cycle sleeping in the lab. A significant finding was discovered as PMDD women 
experienced higher amounts of slow wave sleep (SWS) compared to the control 
participants across the menstrual cycle.  With the use of urine samples they found that 
nocturnal melatonin secretion was characteristically lower in PMDD women compared to 
non-PMDD women, and melatonin has been found to reduce SWS via GABAA-receptors, 
which inhibit SWS (Aeschbach, Lockyer, Dijk, Lockley, Nuwayser, et al., 2009).  Assays 
showed that progesterone was higher during the LL phase compared to the LF phase.  
Therefore, these findings suggest that women with PMDD may be experiencing altered 
levels of SWS due to the blunted level of melatonin concentrations and melatonin’s 
interaction with GABAA-receptors. 
REM sleep disruptions have been associated with affective disorders such as 
seasonal affective disorder (SAD; Koorengevel, Beersma, Den Boer, & Hoofdakker, 
2002) and clinical depression (Palagini, Baglioni, Ciapparelli, Gemignani, & Riemann, 
2013). The REM symptoms in these disorders include short REM latency, increase of 
REM density and shortening of mean latency of eye movements (Wichniak, Riemann, 
Kiemen, Voderholzer, & Jenajcyk, 2000).  Once again, these findings support the theory 
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that estradiol affects oculomotor functioning via the brainstem and the cerebellum 
because SAD and clinical depression may both be characterized by hormonal sensitivity.  
Given that both of these disorders have been related to oculomotor changes in REM sleep, 
one may speculate that the relationship between these disorders and REM variations are 
related to synaptic plasticity changes caused by estradiol. 
The present study investigated the effect of cyclic female estradiol levels on visual 
systems governed by brainstem and cerebellar pathways of the oculomotor systems.  This 
was done with the use of an eye tracking devise in order to assess estradiol’s involvement 
with eye movements, more specifically, the most straightforward closed-loop system: 
retinal-based horizontal SPEM.  
In summary, there is converging evidence of estradiol effects on SPEM functioning 
including SPEM persistence as follows: (1) modulation of estradiol on visual functioning 
including oculomotor activity, due to estradiol receptors having been found in the areas 
of the brain that are involved with SPEM (i.e., the cerebellum and the brainstem), (2) that 
eye movement disruptions (such as the attention-startle-reflex) are present as a symptom 
of PMS-type individuals and there is some evidence that these women may have stable 
estradiol levels throughout their cycle, (3) estradiol is a known mediator of synaptic 
plasticity in select CNS regions, and estradiol has been reported to modulate REM 
oculomotor activity, particularly with groups that are sensitive to hormonal changes such 
as women with PMDD (4) that progesterone (an antagonist to estradiol during the cycle) 
can alter the sensitivities of GABAA receptors (an action known to be involved with 
neural plasticity in a number of CNS systems), and (5) similar GABAergic systems under 
the influence of female steroids have been implicated in cerebellar and other brainstem 
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regions known to be involved with saccadic eye movements and SPEM.  Real-time eye 
tracking measurements of SPEM along with SPEM persistence (i.e., eye movements that 
continue to track after the stimulus has disappeared) was considered in the present study 
to reveal any possible influences of estradiol on one of the more prominent retinal-based 
oculomotor functions, horizontal SPEM. The role of cycling estradiol influences in 
females was examined by using non-PMS-type non-hormonal contraceptive users as 
controls, PMS-type individuals, and Alesse™ users. We hypothesized that estradiol 
cyclicity would be associated with SPEM persistence duration, amplitudes, and 
oculomotor tracking efficiency as defined by target lead (eyes in front of moving target) 
and target lag (eyes trailing behind moving target). We also predict that there will be 
group differences in which the estradiol cyclicity present in the control group will lead to 
changes in eye movements compared to the PMS-type and Alesse™-user groups who 
have putatively different estradiol cyclicity throughout the menstrual cycle. 
Methods 
Participants 
Of the 423 women from Introductory and upper-level Psychology classes at 
Lakehead University screened by the online questionnaire, 66 participated in the 
laboratory portion of the study.  The study was described as an investigation of women’s 
health and visual functioning.  The participants received between one and three bonus 
marks toward their grade in research-participation eligible psychology courses.  The total 
points that the participants were awarded depended on the participants’ length of 
involvement in the study, in which the screening phase and both laboratory sessions were 
worth one point each. All of the participants were females between the ages of eighteen 
and forty-four years (M = 22.42, SD = 0.79), and they were either free-cycling (i.e., not 
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taking hormonal contraceptives, n = 47) or taking the monophasic oral contraceptive 
Alesse™ or the generic form Aviane™ (n = 19).  The Alesse™ users were taking a 
standard quotidian dose of 20 µg of ethinyl estradiol and 0.10 mg of progestin 
levonorgestrel for the duration of their 28-pill package. The mean LF menstrual cycle day 
for the control (M = -14.23, SD = 1.7), PMS-type (M = -14.2, SD = 1.15), and Alesse™ 
user (M = -14.14, SD = 1.35) groups were almost identical.  For the LL menstrual cycle 
phase, the mean cycle day for the control (M = -4.39, SD = 1.59), PMS-type (M = -4.15, 
SD = 1.89), and Alesse™ user (M = -4, SD = 1.5) also showed little deviation from each 
other.  All participants had normal or corrected-to-normal vision, and were screened for a 
history of ophthalmological, and neurological. Further exclusion criteria included: age, 
whether they had been diagnosed with a psychiatric disorder, whether they are/were 
being treated with pharmaceutical agents, and reproductive health. Each participant was 
given a ten-dollar gift certificate to either Chapters or Tim Horton’s in addition to course 
bonus marks for qualifying student participants 
Apparatus 
 Menstrual cycle phase measures. 
 
 Ovulation test strips.  The participants used ovulation test strips that indicated the 
presence or absence of the luteinizing hormone (LH) surge.  The ovulation test strips 
were a part of a kit called the Home Pregnancy Test™ and were designed to detect as 
little as 5 mIU/mL of LH in urine, with a specificity of 99.8%.   The strips were used to 
confirm the correspondence of the free-cycling participant’s position in their menstrual 
cycle with the proper scheduling of the laboratory sessions.  All of the participants used 
the test strips, regardless of their experimental group inclusion (see Laboratory Screening 
below for the group categorization of Controls, PMS-Type, and Alesse™ Users), in order 
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to ensure standardization of the procedures. The proper use of the strips was explained 
thoroughly, and each participant received five strips and five small Dixie cups (to collect 
the urine sample).  It is easiest to detect LH in urine between 10:00 and 20:00, so the 
participants were instructed and asked to use the strips during these times for five 
consecutive days beginning on day 11 of the menstrual cycle. The strips were used by 
inserting the end of the strips into the urine sample for up to ten seconds, followed by a 
ten-minute waiting period before considering the result.  Either a negative or positive 
result for LH occurred, indicated by the presence (positive result) or absence (negative 
result) of a test line adjacent to the control line.  The test line needed to be as dark or 
darker than the control line. A positive result was indicative of an LH surge occurring 
within forty-eight hours. The participants’ late-follicular session was booked to take 
place within 24 hours after they reported a positive result on the test strips, which 
occurred between days 11 and 16 of the menstrual cycle. LL laboratory sessions were 
scheduled between and including days 25 to 27 (or days -2 to -4 using reverse counting – 
see below). 
Reverse counting strategy.  A reverse counting strategy or “backwards counting” 
strategy was used to book the LL session on or between -2 to -4 based on a 28-day cycle 
(Haselton & Gangestad, 2006).  This method of counting backward from the first day of 
the next estimated menstruation is an easy and effective way to estimate menstrual cycle 
day because (1) you estimate the beginning of the next menstruation based on the first 
day of the last menstruation and the individuals reported cycle length, (2) estimate the 
participant’s onset of their next menstruation and count back from there, and (3) confirm 
the day of testing by counting backward from the participants true first day of menses.    
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Further justification for using the reverse counting strategy is that the LL phase duration 
(days) has been reported as including less variability compared to the LF phase  (Jöchle, 
1973; Pillsworth, Haselton, & Buss, 2004).  Therefore, counting backwards from the 
onset of menstruation rather than pinpointing the LL phase prospectively is advantageous 
for this study. 
Salivary collection for estradiol and progesterone assays. As an extra method to 
confirm menstrual cycle position, estradiol and progesterone measurements were attained 
via salivary samples.  Participants were asked to passively drool through an 
approximately 5 cm in length straw into a cryovial.  As a precaution, participants were 
instructed to refrain from using chewing gum, lemon drops, granulated sugar, drink 
crystals, brushing their teeth, and eating a large meal for at least an hour prior to their 
laboratory session.  The participants were asked not to consume alcohol for a minimum 
of 12 hours prior and not eat acidic or high sugar foods for at least 20 minutes before 
their laboratory session.  Salivary sample collection occurred three times during each 
laboratory session until a total of approximately 2 ml of saliva was collected. Each 
laboratory session lasted approximately an hour. The first salivary sample was collected 
after the visual screening procedures (see page 42), followed by the second sample after 
the laboratory questionnaire was completed, and the final sample was taken after the 
completion of the eye tracker test. Collecting the samples three times rather than once 
compensates for the pulsatile release of hormones in order to avoid collecting a sample at 
a trough or peak in levels.  Samples were frozen at -21° until salivary analysis (see page 
46).  






Online screening questionnaire. The screening questionnaire was used to 
categorize the participants into their respective groups which are broken down as follows: 
(1) a control group of women reporting low levels or an absence of PMS symptoms; none 
of whom report the use of hormonal contraceptives, (2) women reporting high levels of 
PMS symptoms, and (3) women reporting the use of the hormonal contraceptive 
Alesse™ or the generic form Aviane™.   The screening questionnaire was also used to 
determine whether the participants met the exclusion criteria (such as age, hormonal 
contraceptive use, whether they had been diagnosed with a psychiatric disorder, whether 
they are/were being treated with pharmaceutical agents, and reproductive health) to 
qualify for the study. 
Several questionnaires were used to screen the participants for PMS symptoms, 
including the Menstrual Distress Questionnaire (MDQ) (Moos, 1968) and the Lakehead 
Inventory of Premenstrual Symptoms (LIPS), which is a 33-item measure of PMS 
severity that was created for Meghan Richard’s dissertation (Richards, 2011).  
Confounding of other affective disorders was also screened for using the Hamilton 
Rating Scale for Depression (Hamilton, 1960) to screen for depression, the Seasonal 
Assessment Pattern Questionnaire (SAPQ) (Rosenthal et al., 1984) to collect information 
on seasonal patterns of mood disturbance, and finally the Beck Anxiety Inventory (BAI) 
(Beck, 1990) was used as a post-hoc measure to ensure that the participants did not differ 
based on level of anxiety symptoms.   
Menstrual distress questionnaire (MDQ).  The MDQ (Moos, 1968) is a 47-item 
questionnaire that is rated on a five-point scale ranging from “0” (no experience of the 
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symptom) to “4” (present/severe).  The items assess current symptom experience within 
the last 24 hours (MDQ-T) as well as current presence or experience of symptoms during 
the following three phases of the most recent cycle: menstrual, intermenstrual, and 
premenstrual (MDQ-C).  Eight scales on the MDQ are used to assess pain, concentration, 
water retention, behaviour change, negative affect, autonomic reactions, arousal, and 
control.  The MDQ-T and the MDQ-C were used to select participants to their respective 
groups. The MDQ-T was used in the lab as a prospective measure of pms-type symptoms, 
while the MDQ-C was used in the screening questionnaire as a retrospective measure.  
Lakehead inventory of premenstrual symptoms (LIPS).  The LIPS is a 33-item 
scale developed as part of an unpublished dissertation (Richards, 2011).  It is a 
retrospective self-report measure of the extent to which participants meet the criteria for 
PMDD. It can also be used, as it is here, to assess the severity of one’s typical level of 
pms-type symptoms. This questionnaire includes three questions that meet each of the 
eleven criteria listed in the DSM-IV.  The three questions include: (1) the frequency with 
which each set of symptoms is experienced, (2) the degree to which each symptom 
impairs work, school, or interpersonal performance/functioning, and (3) the severity with 
which each symptom is experienced.  The questions are rated on a seven-point Likert-
type scale anchored by “0” (not at all) on one end and “6” (extremely) for the latter two 
categories of questions and “6” (frequently) for the first category. The women were also 
asked to report if the symptoms from the questions occur in more menstrual cycles than 
not over the previous 12 months.  Possible scores on this questionnaire range from 0 to 
198, and higher scores are indicative of greater severity of symptoms as well as higher 
degree of impairment. 
Running head: SPEM AND ESTRADIOL 
 
40 
Hamilton rating scale for depression (HRSD).  The HRSD (Hamilton, 1960) 
assesses current symptoms of depression. The scale includes a likert-type rating scale that 
ranges from “0” (not at all) to “4” (marked or severely) for 28 items that assess patterns 
of diurnal variation, depersonalization, obessions/compulsions, paranoia, and 
atypical/vegetative symptoms.  Participants whose scores meet or exceed 20 were 
excluded from the study as this was the criteria outlined in a study that screened for 
Seasonal Depression (a disorder that has several overlapping symptoms with PMS) 
conducted by Wesner and Tan (2006).  O’Hara and Rehm (1983) report that the 
intraclass correlation for HRSD was .91 (p < .0001) when rated by expert raters and .76 
(p < .0001) by novice raters.  The criterion validity estimates were determined using 
comparisons between the means of the novice and expert raters.  The mean of the expert 
ratings (M = 14.50; SD = 7.42) was not significantly different, t(19) = 1.81, p > .05, from 
the mean of the novice raters (M = 13.72; SD = 6.82). 
Beck anxiety inventory (BAI). The BAI is a measure of self-reported anxiety 
(Beck & Steer, 1990).  It includes a four-point scale where “0” indicates a response of not 
at all, “1” is mild, “2” is moderate and “3” is severe.  The four-point scale is used to rate 
21 descriptive anxiety symptoms.  According to Beck et al. (1988), the BAI had high 
internal consistency (Cronbach coefficient alpha = .92) and a high test retest reliability 
of .75.   
Seasonal assessment pattern questionnaire (SAPQ).  The SAPQ (Rosenthal et 
al., 1984) asks participants about their seasonal variations in mood, weight, appetite, 
sleep length, social activity, concentration, and energy.  The SAPQ has been shown to 
have high reliability and validity (Magnusson, Friis, & Opjordsmoen, 1997).  The SAPQ 
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was included as a means to assess PMS in future studies, but was not used in the present 
study. 
Laboratory questionnaire. During each laboratory session the participants were 
asked to complete a brief questionnaire (Richards, 2011; see Appendix F) asking whether 
or not they were taking pain medication, or if they had consumed alcohol or caffeine in 
the last twenty-four hours.  Participants were also asked to indicate how much sleep they 
had attained prior to attending the lab for testing, and they were asked to answer 
questions regarding their current affective state.  The Positive and Negative Affect Scale 
(PANAS) (Watson, Clark, & Tellegen, 1988) as well as the Menstrual Distress 
Questionnaire (MDQ) were included in the Laboratory Questionnaire. The PANAS 
includes two scales: positive affect (PA) and negative affect (NA).  High scores on PA 
were interpreted as reflecting high energy, concentration and engagement. Low scores on 
PA were interpreted as sadness and lethargy.  High scores on NA reflect greater degrees 
of subjective distress and unpleasant mood states such as anger, contempt, and disgust, 
whereas low scores were interpreted as calm and secure. Each item was rated on a five-
point scale from 1 (very slightly or not at all) to 5 (extremely).  Like the SAPQ, these 
ratings were not assessed in the present study, but were included for future analyses. 
Three scales from the Menstrual Distress Questionnaire (MDQ)-T was included in 
order to asses menstrual cycle related pain and/ or discomfort.  The items in the 
laboratory questionnaire reflected the following three scales: pain (six questions), water 
retention (four questions), and negative affect (8 questions).  These scales were used to 
prospectively confirm the presence of PMS symptoms during group classification. 
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Screening for visual acuity. A Freiberg visual acuity test (FrACT; Bach, 1996; 
2007;) was used in order to determine whether each participant had the necessary visual 
acuity to qualify for the study.  During the FrACT participants were presented with 
Landolt “C” stimuli on a 75 cm distanced, 24° high x 18° wide CRT monitor.  The 
Landolt “C” was presented at various orientations and participants were asked to 
determine which of 8 directional orientations the “C”-gap was pointing to.  The gap of 
the Landolt C varied from 1° to 5’ visual angle.  The size of the gap that was properly 
detected 75 percent of the time determined threshold.  Acuity estimates were attained 
using a PEST (Parameter Estimation by Sequential Testing) procedure in which the delta 
iteration in gap size was based on the participants prior test response. Participants were 
asked to use a chin-rest to ensure that they viewed the stimuli from the proper distance.  
Gap direction responses were made on a keyboard number pad. The information acquired 
from the FrACT was used to ensure that the participants had the near visual acuity 
required to participate in the study. An example of the FrACT stimuli and keyboard 
configuration is shown in Figure 2. 
Visual screening for colour vision.  The Ishihara pseudoisochromatic plate test, 
24-plate edition (Ishihara, 1993) was used to determine whether the participants met the 
criteria for normal trichromatic color discrimination.  The test included 24 plates (see 
Figure 3) that assess whether or not the participants showed deviations on the protan, 
deutan, or tritan lines. Each plate showed number patterns within an array of 
equiluminant colored dots to determine whether participants showed signs of dichromatic 
colour blindness.  The plates were viewed under a D-65 standard illuminant lamp. 
Participants who could not read at least one of the plates were asked to discontinue their 
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participation without bonus mark penalty. Colour blindness screening was required 
because of the chromatic “yellowness” of the SPEM target that was designed to ensure L- 
and M-cone activity over an S-cone system that is influenced by estradiol (Eisner et al., 
2004). 
Eye tracking calibration.  The eye tracking procedure was an adaptation of 
Smyrnis et al. (2007). We used a Cambridge Systems, infrared eyetracker [Cambridge 
Research Systems (CRS), Rochester, UK].  The participant dark-adapted for seven 
minutes before performing the calibration phase of the eye tracker test. During the 
calibration, the participant was instructed to first look at the fixation target and then to 
focus on the target where-and-when it was presented.  Calibration values were used to 
determine saccade patterns. The moving stimuli (the targets) were presented on a 22-inch 
Mitsubishi Diamond Pro 2070 monitor powered by a CRS ViSaGe stimulus generator 
with 14-bit resolution per color channel at a 200 Hz frame. A Dell Precision Workstation 
with a Pentium 4 processor running at 3.6 GHz Calibration and gamma-correction of the 
software provided with the ViSaGe system was the source for driving the monitor. 
The eyetracking calibration phase began with the participants being presented 
with a target (“white” square 0.5 x 0.5°) that appeared at the center of the monitor.  After 
starting at the fixed center position, the target moved from right to left at constant 
intervals (2 seconds) in either 5° or 10° distances, and then back to the center. Both the 5° 
and 10° movement-cycles were repeated twice so that there were a total of four saccades 
for each of four positions (left/right, 5/10°) recorded.  When necessary, left/right 
differences in amplitude were corrected with a manual adjustment and the calibration 
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procedure was repeated. Following the calibration phase, the experimental procedure 
began (see Procedure below). 
Procedure 
Participant orientation to menstrual cycle scheduling.   Participants were 
provided with a link to the online questionnaire (see Appendix A) that included the 
consent form, a brief review of the study (Richards, 2011), and a screening questionnaire 
during the recruitment phase of the study. Those who were qualified according to the 
participation criteria (see page 33) were contacted by telephone or e-mail and asked to 
meet with the researcher for an orientation session.  The orientation consisted of the 
researchers describing each of the psychophysical tests, the laboratory questionnaire, the 
salivary sampling procedures, and the ovulation test strip procedures, so that the 
participant knew what to expect during their laboratory sessions. During this time, the 
researchers made a preliminary appointment (to allow for adjustments) to book the 
participant’s first laboratory session based on her self-report of her last first day of 
menses (as well as the length of her menstrual cycle) as indicated by her Alesse™ 
package for the oral contraceptive users, or by the reverse counting strategy for the non-
users.  LF sessions for the non-oral contraceptive users were scheduled based on the 
same self-reports described above and confirmed using the LH test strips (see page 35).  
For the Alesse™ users, day one of the menstrual cycle typically occurs on or around pill 
21 in a 28-day package. Therefore, the LF session was scheduled between the daily pills 
8-11, and LL session was scheduled between pills 18-21. The rest of the participants 
were scheduled for the LF session on days 11-14 and the LL session was scheduled 
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between and including days 25-28.  Confirmation of next menses from each subject was 
used to ensure that the laboratory sessions were correctly scheduled.  
 Laboratory session procedures.  Following the completion of the consent form 
(see Appendix D), the participants completed the laboratory questionnaire, the first 
portion of the salivary sample was collected, and then the FrACT (see Figure 2) and the 
Ishihara pseudoisochromatic plate test (see Figure 3) were conducted to ensure the 
participants’ eligibility. One error on the Ishihara and a near acuity of 0.3 minimum angle 
resolution or greater on the FrACT were the qualifiers for participation. The researcher 
then collected the second portion of the salivary sample and then the eye tracking 
calibration was done. The final portion of the salivary sample was collected after the eye 
tracking test; therefore it took approximately an hour to complete the full sample. 
Laboratory testing. 
Eye tracking experiment. During the testing phase (after successful track 
calibration), the participants were first instructed to focus on a fixation target.  They were 
then asked to follow a horizontally moving “yellow” round target (80 cd/m2) with a 
subtending visual angle range of  ±13° from fixation center (see Figure 4). The stimulus 
was superimposed on a “gray” background (mean luminance of 23.1 cd/m2).  Again, the 
target was “yellow” and not “white” because we wanted to ensure primarily parvocellular  
L and M cone involvement with little koniocellular responsivity (see Eisner et al., 2004).  
Target frequencies (cycles/sec or Hertz, Hz) were presented at 0.25, 0.5, and 1.0 Hz 
averaged over 10 cycles per frequency. Infrared Purkjinje-image positions were acquired 
as x,y, ASCI files and downloaded to a large memory Apple storage facility (RAID 
system) that was linked to a network server in order to back-up the data and prevent 
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excessive memory demands on the Dell hard drive. To measure tracking persistence, we 
used the data that was collected during the same frequencies described above (0.25, 0.5, 
and 1.0 Hz); however, instead of simply looking at the repeated 10 cycles we assessed 
the data that was collected after the stimulus disappeared wherein the eye movements 
were timed for 2 seconds. 
Following the completion of the test, the final portion of the salivary sample was 
taken.  Lastly, the participant’s next laboratory session was scheduled.  If the next session 
was during the LF phase, then the participant was re-instructed on the proper use of the 
hormone test-strips. 
Second laboratory session. With the exception of signing the consent form, and 
completing the FrACT and the Ishihara Plate Test, all of the procedures from the first 
laboratory session were repeated again for the second session.  The participants were 
debriefed following their completion of the study and given the ten-dollar gift certificate 
to either Chapters or Tim Horton’s. 
Salivary assay for estradiol and progesterone. Enzyme Linked ImmunoSorbent 
Assay (ELISA) was the method used to analyze the samples.  Analysis occurred in the 
Lakehead University Center for Biological Timing & Cognition Bioassay Lab (BAL).  
The analysis followed a standardized Salimetrics™ protocol (see kit description in 
Appendices G and H). 
The plates were arranged a priori, where samples were thawed, vortexed, and 
centrifuged at 1500 g for 15 minutes.  Five microcentrifuge tubes were filled with 300-
mL assay diluent and labeled 2 through 6, respectively.  The 32 pg/mL standards (tube 1) 
was then serially diluted 2x by removing 300 ml and adding it to tube 2.  This procedure 
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was repeated for tubes 3 through 6 creating final standard concentrations of 32 pg/ml, 16 
pg/mL, 8 pg/mL, 4pg/mL, 2 pg/mL, and 1 pg/mL for tubes 1 through 6 respectively.  
Adhering to the a priori plate layout, 100 ml of standards, unknowns, and controls were 
pipetted into corresponding wells.  All samples were assayed in duplicate.  One-hundred 
ml of assay diluent was used in each non-specific binding (NSB) well.  Using a 1:800 
dilution, 100 ml of enzyme conjugate, (15 ml of enzyme conjugate and 12 mL estradiol 
assay diluent) was added to each well using a multi-channel pipette.  The plate was then 
covered with adhesive covering and mixed on a Bokel® Scientific Model 130000 plate 
rotator for five minutes at 500 rpm and incubated at room temperature for 115 minutes.  
Following incubation the plate was washed with a Molecular Devices Skan Washer 400 
plate-washer four times with 1x wash buffer.  Two-hundred mL of tetramethylbenzidiene 
(TMB) solution was then added to each well using a multichannel pipette.  The plate was 
then mixed on a plate rotator for five minutes at 500 rpm and incubated in the dark at 
room temperature for 25 minutes.  Fifty mL of stop solution was then added using a 
multichannel pipette.  Samples were subsequently mixed on a plate rotator for three 
minutes at 500 rpm.  Finally, samples were read in a Molecular Devices SPECTRA max 
384 plus plate reader at a 450 nm setting for concentration count and 660 nm setting for 
zero optics calibration.  Final calculations were computed by subtracting the average 
optical density (OD) for the NSB wells from the average OD of the zero, standards, 
controls, and unknowns.  Percent bound for standards, unknowns and controls was 
calculated by dividing the average OD by the average OD for the zero. Hormone levels 
were examined for group and menstrual cycle phase differences. 




 Screening for group inclusion.  Three exclusion criteria were used to classify the 
participants to either of the Control, PMS, or Alesse™ users (oral contraceptive user) 
groups both before and after the laboratory sessions. The first criterion (used prior to any 
laboratory involvement in the study) was the retrospective mean premenstrual phase 
MDQ-C scores collected from the online screening questionnaire (N = 423).  Participants 
who had scores above the mean were assigned a “1” (PMS-type) and those with scores 
below the mean were assigned a “0” (Control or Alesse™ users).  The second criterion 
was a prospective measure of PMS symptoms taken from the laboratory MDQ-C scales 
that were tested twice--once during the LF phases and once during the LL phases.  Those 
who scored higher during the LF phase were coded as a “1” while women whose scores 
remained the same or were lower during the LL phase were assigned a “0”.  The final 
step was to calculate the mean score on the LIPS for the entire sample of participants 
who completed the online screening questionnaire (N = 423).  In line with the previous 
coding system, “1”s and “0”s were assigned to participants who scored higher than the 
entire sample mean and lower than the sample mean, respectively.  Participants who were 
not taking oral contraceptives and were assigned two or more “1”s were selected for the 
PMS-type group.  Non oral-contraceptive users that received less than two “1”s were 
included in the Control group. Using the three criteria, 23 participants were classified as 
non- users without PMS-type symptoms (Control group), 22 as nonusers with PMS-type 
symptoms, and 21 as Alesse™ and/or Avianne™-users. .   
 Salivary assay for estradiol and progesterone. Concentrations of controls and 
unknowns were determined using SoftMax Pro® software through interpolation with a 4-
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parameter sigmoid minus curve fit. We determined averages of all repeats for estradiol 
and progesterone as well as the coefficients of variability (CV).  We confirmed all values 
to percent Inter-Assay CV and Intra-Assay CV limits. CVs were calculated from the 
calculated concentrations, Inter-assay % CVs of less than 15 were acceptable and Intra-
assay % CVs less than 10 were included.  The calculated concentrations (x) were 
determined by a four-parameter descending equation fitted to the standard known 
concentrations: 
Eq 1. x = c [ ( -a + y ) / d – y ) ] 1 / b  ; 
where b is the slope, a is the low x-value asymptote and d is the high x-value and d is the 
high x-value asymptote, and c is the midpoint parameter between a and d. 
 Real-target (stimulus present) database. Participant eye positions (amplitudes) 
for every corresponding discrete 20 msec time stamp was converted from millimeters 
(mm) to degrees visual angle by multiplying the amplitude by a subtending angle of 
0.075.  Next, each participant’s eye movements were averaged across ten full cycles to 
calculate the average amplitude-per-time-stamp.  Noise reduction was achieved through 
signal averaging with the original ten repeated cycles over 40,000, 20,000, and 10,000 
msec for the 0.25, 0.5, and 1.0 Hz frequencies, respectively. A cutoff amplitude of ±20 
visual angle was used to filter out saccadic and eye-blink responses. 
 Average position (real target amplitude).  The average across 10 full cycles of 
the real-target was calculated for each participant by menstrual phase and by frequency.  
The averages were used to examine the average eye position within the -13° to 13° range.  
Findings from the average position were used to corroborate findings from the lead and 
lag as well as to determine any directional eye position biases. 
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 Lead and lag (real target).  Data from the real-target averaged across 10 full 
cycles were used to assess whether the participants eye movements were ahead of (lead) 
or behind (lag) the target stimulus.  Only eye movements recorded after 90° and before 
270° phases were coded as lead or lag in order to assess one part of the sine wave where 
the eye movements were moving at the fastest velocity (through center position) and did 
not have the opportunity to catch up to either extreme excursion point on the screen (-13˚ 
or 13˚).  While the eye was moving from -13˚ to center all positive amplitudes were 
coded as leads and negative amplitudes were coded as lags, and while the eye was 
moving center to 13˚ all positive amplitudes were coded as lags and the negative 
amplitudes were coded as leads. A nonparametric count was made to sum the total count 
of leads for averaged groups, menstrual cycle, and frequency. The lead count was divided 
by the total number of 20 msec time bins for one averaged real-target cycle examined 
from 90˚, passing through 180˚, and ending at 270˚ to determine the percentage of 
average lead.  This percent average lead was used to assess SPEM latency with > 50% 
representing eye movements that were ahead of the target. 
 Terminated target database (extrapolated trajectory).  Eye movements following 
the termination of the target was collected for 2 seconds as a means to assess eye 
movement persistence.  Persistence data was also converted to amplitude degrees and 
filtered for eye blinks and saccades using the same criterion as the real-target data.  
Stimulus offset was programmed to be randomized to begin at one of four cardinal phase 
positions within its current cycle; either 0°, 90°, 180°, or 270°.  The participants’ cycle 
phase termination positions were recorded manually for both phases of the menstrual 
cycle and for all three frequencies using their real-target database.  The onset of 
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termination was flagged by the Matlab programming by a double “2” beside the original 
time-stamped data.  Sinusoidal cycle phase points were manually marked throughout 
each participant’s dataset to determine the exact sinusoidal cycle phase where the target 
terminated and where persistence began.  
 The extrapolated trajectory (i.e., where the participants eye movements would be 
based on the ten-cycle average of each participants eye positions with a real target) was 
calculated for all frequencies and menstrual phases by using the following steps.  
The real-target ten-cycle tracking averages (per-participant, per-menstrual phase 
and per-frequency) were entered into a Matlab dataset as a function of time; where time 
in msec was converted to seconds. The following equation was a Matlab curve fitting 
procedure used to fit a Fourier transform of the data into sinusoidal fundamentals: 
Eq 2. f(x) = a0 + a1 • cos (x • ω) + b • sin (x • ω)   
where the parameters a0 was the x-intercept; a1 was the amplitude, b was the range of 
excursion from center (i.e., ±13° visual angle from center screen; and ω was the temporal 
frequency).  The goodness of fit was determined using R2 and any menstrual phase 
and/or frequency-per participant model fit below a moderate R2 (0.4 or lower) was 
eliminated from future analysis (see Hu, 2014). 
The coefficient values from the Fourier transform fits were then entered into an 
Excel™ spreadsheet where the optimized fitted equation was used for each participant’s 
menstrual phase and frequency data.  These calculations provided a theoretical trajectory 
of where the eye movements would have been (again, in amplitude degrees visual angle) 
if the stimulus had not been terminated; therefore these calculations were subsequently 
referred to as the theoretical extrapolated trajectory after target offset.  The extrapolated 
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trajectories were aligned with relative time stamps beginning at 0 (start point after target 
termination) to the ending time of 2 seconds (i.e., the full recording epoch after offset).  
Note that the theoretical trajectory time stamp was normalized so that the 0 time stamp 
always factored in the randomized offset for each participant.  Again, randomized offsets 
were either at the 0°, 90°, 180°, or 270° phase of all frequency cycles; therefore, I will 
subsequently refer to the onset of termination as the relative onset of termination and 
time as relative time. 
Our next step was to calculate the difference in amplitude between the extrapolated 
trajectory and the real eye movements in order to assess a statistical level of persistence 
(i.e., how long the participant’s eye movement was following the extrapolated trajectory 
after termination). A two-tailed, 95 percent confidence interval was calculated for every 
discrete time stamp as well as overall confidence interval calculations (per menstrual 
phase and frequency) from the 10 full cycles obtained from the real-target database.  
Both confidence interval measures (individual time-stamp and overall) were relatively 
consistent in indicating when the participant’s eye-movements went off-track from the 
extrapolated trajectory, so we calculated the individual deviations as the “delta” indicator 
for when (in msec) the participants’ no longer showed persistence movement.  In these 
calculations, we filtered out “0”s and amplitudes outside of the excursion range of -13° to 
13° and then took the absolute value of the participants amplitude subtracted from the 
extrapolated trajectory (i.e.,  |theoretical amplitude| - |actual eye movements|  ). That 
value provided the difference score for each discrete time-stamp.  When the participant’s 
eye position (amplitude) deviations exceeded the respective time-stamp confidence 
interval, that time stamp was selected as the point in time when the participants no longer 
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persisted with their tracking movements. From this point in time to the time of target 
offset defined persistence duration (see Figure 8).  Further, we plotted eye position 
(amplitude in deg visual angle) as a function of time was for every participant as a non-
statistical graphical means of qualifying and confirming the persistence duration and 
extinction. Sample plots of individual tracks for the control, PMS-type and Alesse™-user 
group by menstrual phase and frequency are shown in Figures 9-11, respectively.  
 Amplitude decline of eye movements.  In order to compare the difference in 
persistence properties between groups by menstrual cycle phase and frequency, we 
converted the delta calculations (see above) to a percentage of eye movement accuracy 
with respect to the relative theoretical extrapolated trajectory using the formula: 
Eq. 3. (1- [ |x-A| /R ] ) • 100  ; 
where x is the theoretical position of where the target would be in degrees visual angle if 
it were not terminated (i.e., extrapolated trajectory), A is the eye position (in deg visual 
angle amplitude), and R is the full amplitude range from center screen (which we defined 
as 20° instead of 13° to avoid negative values).  This formula allowed the calculation of 
the percent tracking accuracy for each derived delta score per relative time stamp.  From 
there, the averages were calculated for every relative time-stamp for each group, across 
menstrual phase (LL, LF) and across frequency (0.25, 0.5, 1.0 Hz).  The total cross 
averages were plotted as a function of relative time for the control, PMS-type, and 
Alesse™ user groups (see Figures 14-18, Column A). A second set of plots (Figures 14-
18, Column B) show the same cross averages in Column A excluding data that fell within 
the relative extrapolated target position on the return leg towards center (0°) from the 
peak left (90° phase) or peak right (270° phase), which is referred to here as the rebound 
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limb. These rebounds cause artificial inflations in percent accuracy such that even if the 
participants’ eye positions were to steadily stare at center screen, the resultant returning 
trajectory would impose a smaller delta, and thus a recalculation of “on-track” accuracy.  
Figures 12 and 13 highlight in red which of the limbs of the 0.5 and 1.0 Hz trajectory 
were isolated to eliminate this rebound effect.  The red time ranges outlined at the bottom 
of each respective plot also indicate those intervals that were kept to better estimate the 
decay. The slowest 0.25 Hz trajectory was not used in the analysis due to a sizeable noise 
factor. The statistically derived persistence termination is indicated on the plot with a 
black arrowhead.  A decay function was fit to both Column A and B data sets to better 
delineate the percent accuracy declines in amplitude: 
Eq. 4.  y = b • e (-m • x)   ; 
where x is relative time, b is the y-intercept and m defines the slope starting at the onset 
of consistent decay (i.e.,  following the onset of the statistically derived offset of 
persistence when the eye movements were no longer within the 95% confidence interval 
range previously described). 
Results 
 
Our hypotheses predicted that estradiol would have differential effects on SPEM 
and therefore we expected variation in SPEM across our groups (Control, PMS-type, and 
Alesse™ users), target frequencies (0.25, 0.5, and 1 Hz), and across menstrual cycle 
phase (LF, LL).  The SPEM-tracking variables included (1) persistence time, (2) 
amplitude decline of eye movements, (3) lead and lag, and (4) average amplitude 
(position) differences.  The null hypothesis predicted that persistence time, lead and lag, 
and average position would not vary according to the previously stated factors. Linear 
Running head: SPEM AND ESTRADIOL 
 
55 
Mixed Models (LMMs) were performed to analyze the data with group classified as a 
mixed-fixed factor and menstrual cycle phase and frequency specified as both mixed-
fixed and mixed-repeated factors.  LMM was selected as opposed to Repeated Measures 
Analysis of Variance (rmANOVA) because LMM allows for full factorial analysis for 
both between and within subjects variables without excluding pairwise missing data. The 
dependent variables were persistence time after target termination, lead and lag, and eye-
movement position. This research design was determined a priori and consisted of a 
mixed 3 X 2 X 5 Between (Group: [Control, PMS-type, and Alesse™ users]) X Within: 
(Menstrual Cycle Phase [MF, LL]) X Frequency (0.25, 0.5, 1.0, 1.25, 2.0 Hz) using 
Bonferonni adjusted alpha levels. Alpha was set at p < 0.05. 
Salivary Assay for Estradiol and Progesterone 
There are several findings to note from the estradiol and progesterone assays. 
Beginning with estradiol, there was a main effect for group F(2, 51.97) = 4.22, p = 0.02.  
The PMS-type group (M = 5.09, SD = 0.56) was significantly different from the Alesse™ 
users (M = 3.76, SD = 0.21) (p = .05) (see Figures 6 and 7). In fact, the PMS-type group 
had the highest overall concentration of estradiol across the menstrual cycle compared to 
the other groups.  Although the group x menstrual phase interaction was only 
approaching significance F(2, 51.97) = 2.64, p = 0.08, a pairwise comparison across all 
groups revealed that the mean differences in estradiol concentration between the LF 
phase (M = 4.94, SD = .32) and the LL phase (M = 3.94, SD = .25) was significantly 
different (p = .02) for the controls. Interestingly, neither the PMS-type nor the Alesse™ 
user groups showed significant differences in estradiol concentration between menstrual 
cycle phases.  
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The results for progesterone also revealed several noteworthy findings.  There was 
a main effect for menstrual cycle phase, F(1, 66.59) = 5.52, p = .02).  The participants 
had higher progesterone concentrations during the LL phase (M = 162.27, SD = 12.85) 
compared to the LF menstrual cycle phase (M = 125.91, SD = 8.93).  Although there was 
not a significant interaction effect for group x menstrual phase, an analysis of the 
pairwise comparisons revealed that both the control group (p = .03) and the PMS-type 
group (p = .05) had significant progesterone concentration differences between the LF 
and the LL phases.  For the control group, progesterone was significantly higher during 
the LL phase (M = 166.58, SD = 13.53) compared to the LF phase (M = 124.19, SD = 
13.66).  With regards to the PMS-type group, the LL phase (M = 202.15, SD = 31.68) 
also showed significantly higher progesterone concentrations relative to the LF phase (M 
= 131.26, SD = 14.01).  The Alesse™ user group did not show significant shifts between 
the menstrual cycle phases. 
Follow-up paired samples t-tests confirmed the above findings.  For estradiol, the 
control group had significant differences between menstrual phases t(21) = 3.46, p = .002, 
whereas the PMS-type and Alesse™ user groups did not show significant differences.  
For progesterone, both the control group, t(16) = -2.20, p = .034, and the PMS-type group, 
t(18) = -2.16, p = .045, had significant differences between menstrual phases while the 
Alesse™ user group did not (see Figures 6 and 7).  The salivary assay results 
demonstrate that, for estradiol, the control group showed a change across the menstrual 
cycle phases.  The PMS-type and Alesse™ user group did not show a change across the 
menstrual cycle for estradiol.  Therefore, if there are group differences in SPEM 
functioning and persistence that differentiate the control group from the PMS-type and 
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Alesse™ users then this suggests that estradiol is involved.  However, the results for 
progesterone showed a menstrual cycle phase effect for the control group and the PMS-
type groups.  There was not a change in progesterone between menstrual phases for the 
Alesse™ user group.  Therefore, if significantly different oculomotor effects are found 
for the control and PMS-type groups compared to the Alesse™ user group, then this 
suggests that progesterone is involved (see Table 1). 
Table 1     
Sex steroid levels at Late Follicular and Late Luteal for estradiol and progesterone for 
the control, PMS-type, and Alesse™ user groups.  For estradiol, the control group 
showed a significant change across the menstrual cycle but the PMS-type and Alesse™ 
users did not.  For progesterone, there was a significant main effect for menstrual cycle 
phase for the control and PMS-type groups, but not the Alesse™ user group. 
 
Group    Estradiol    Progesterone 
Control   change    change 
PMS-Type   no change   change 
Alesse™ Users  no change   no change 
 
Eye-Movement Position (Real Target Amplitudes) 
Unfortunately, there were no significant menstrual cycle phase effects found for eye 
position. There was a significant group main effect that was observed between the control 
group (M = 0.08, SD = 0.11) and the Alesse™ users (M = 0.56, SD = 0.12) for average 
amplitude.  The PMS-type group also had higher average amplitudes compared to the 
control group (M = 0.39, SD = .10). Finally, a group by frequency interaction effect was 
found with the 0.5 Hz trials, where the Alesse™ users (M = 0.55, SD = 0.20) and the 
PMS-type (M = 0.027, SD = 0.19) showed a left-to-right bias evident by their pattern of 
positive positional eye-movements overall compared to the Control group (M =-0.03, SD 
= 0.18) who had negative overall positional eye-movements (see Figure 19 and Table 2).  




     
Linear Mixed Model analysis of real target amplitude (position) showing a group main 
effect where the Alesse™ user group had higher amplitudes compared to the control 
group and a group by frequency interaction where the PMS-type and Alesse™ user 
groups showed a left-to-right excursion bias whereas the control group remained closer 
to the center of the screen. 
 
Variable   df        F      p 
Group    2   4.776   .009 
Phase    1    0.223    .637 
Frequency   2   1.170   .313 
Group x Frequency  8   2.499   .014 
Group x Phase    2    2.063    .129 
Phase x Frequency  2   0.191   .827 
Group x Phase x Frequency 4   0.230   .921 
 
Lead and Lag (Real Target) 
No menstrual cycle phase effects were found. There was a frequency main effect 
observed for lead and lag, F(2, 166.50) = 6.09, p = 0.003 (see Figure 20 and Table 3).  A 
consistent pattern for the frequencies was found where the participants’ eye-movements 
lagged behind the target more than they were leading the target. Therefore, although we 
are using the “percentage of lead” metric, the results showed that the participants’ eye-
movements were in fact lagging behind the target (i.e., under 50%).  There was not a 
higher percentage of lead for 1.0 Hz (M = 49.52, SD = 1.12), compared to the 0.25 Hz 
target (M = 46.23, SD = 0.78) and the 0.5 Hz target (M = 44.12, SD = 1.10).  There were 
no significant interaction effects observed for lead and lag; however, groups did approach 
a main effect, F(2, 236.08) = 2.69. p = 0.07.  The PMS-type group (M = 45.81, SD = 
0.96) and the Alesse™ user group (M = 45.54, SD = 1.07) showed more eye-movement-
to-target lag compared to the control group (M = 48.53, SD = 1.00) (see Figure 21).  





Linear Mixed analysis of real target lead and lag showing a frequency main effect where 
there was an average lag for eye movements at all of the frequencies and there was a 
trend found for the groups in which the PMS-type and Alesse™ user groups had more 
lag compared to the control group. 
 
Variable   df        F      p 
Group    2   2.691   t.070 
Phase    1   2.682   .103 
Frequency   2   6.094   .003 
Group x Frequency  4   0.481   .750 
Group x Phase   2   1.693   .186 
Phase x Frequency  2   0.029   .971 
Group x Phase x Frequency 4   0.074   .990  
t approaching significance 
Persistence Time after Target Termination (Extrapolated Trajectory)  
There were no significant menstrual cycle phase effects for persistence time after 
target termination; however, there was a frequency main effect, as expected given that 
the speed of a target at a higher frequency should cause greater off-target variations in 
SPEM (see Figure 22).  Participants had longer durations of persistence after target 
termination when tested with the 0.25 Hz oscillating target (M = 0.38, SD = 0.02) 
compared to the 0.5 Hz target (M = 0.27, SD = 0.02) and the 1.0 Hz oscillating target (M 
= 0.28, SD = 0.02).  A group by frequency interaction effect was observed in which the 
PMS-type group had a significantly different persistent duration compared to the controls 
during the 1.0 Hz frequency trial, where the controls (M = 0.32, SD = 0.03) persisted 
longer than the PMS-type group (M = 0.21, SD = 0.03) (see Figure 23). These effects can 
be seen in Table 4.  






Linear Mixed Model analysis of duration of persistence after target termination showing 
a frequency main effect in which there was longer persistence durations during 0.25 Hz 
compared to 0.5 and 1.5 Hz. A group by frequency interaction effect revealed that the 
PMS-type group persisted for shorter durations compared to the control group during at 
1.0 Hz. 
 
Variable   df        F      p 
Group    2   0.644     .526 
Phase    1   0.011     .916 
Frequency   2   8.104   <.001 
Group x Phase   2   0.402     .669 
Group x Cycle 
Phase x Frequency  2   0.132     .876 
Group x Phase x Frequency 4   0.803     .525 
 
Amplitude Decline of Eye Movements (Extrapolated Trajectory) 
The results of the decay functions were not assessed statistically because 
logistically we could not run multiple repeating trials for sufficient signal averaging and 
still keep within a reasonable time frame for experiment participation.  Instead, we 
analyzed the fitted decay function slopes for group, menstrual cycle phase, and with 
frequencies to look for trends. Using the fitted slope parameters averaged across groups 
and across menstrual cycle phases for both 0.5 and 1.0 Hz we compared the slopes 
calculated in Part B (fitted decays separated by sinusoidal limbs; see Figures 14-18).  
Column A (total decay; see Table 5 and 6 showing the slope parameters) reveals 
sufficient noise compared to the data where the rebounds were isolated and removed 
(Column B). Therefore, the slopes derived for Column B were further analyzed and 
shown in Figures 14-18. 





Slope parameters of the fitted decay function to the calculated percent accuracy 
amplitudes (see eq. 2) for the 0.5 Hz condition. The limbs are defined as those amplitudes 
on the return leg towards center (0°) from peak left (90° phase) or peak right (270° 
phase). NOTE: The number of limbs indicates the number of times the participants kept 
from reaching 0% accuracy with each rebounding extrapolated trajectory. 
  
Group    Limb  Fitted Slope  R2  
Control   1  1.3978   0.948 
Control   2  3.1257   0.921 
PMS-type   1  1.4823   0.910 
PMS-type   2  2.4849   0.961 
Alesse    1  1.1349   0.945 
Alesse    2  1.4424   0.781 
Late Follicular   1  1.4951   0.954 
Late Follicular   2  3.041   0.928 
Late Luteal   1  1.056   0.974 
Late Luteal   2  2.1134   0.945 
R2 > .5 (see Hu, 2014). 
 





Slope parameters of the fitted decay function to the calculated percent accuracy 
amplitudes (see eq. 2) for the 1.0 Hz condition. The limbs are defined as those amplitudes 
on the return leg towards center (0°) from peak left (90° phase) or peak right (270° 
phase). NOTE: The number of limbs indicates the number of times the participants kept 
from reaching 0% accuracy with each rebounding extrapolated trajectory. 
  
 Group    Limb  Fitted Slope  R2  
Control   1  1.401   0.89 
Control   2  3.7601   0.96 
Control   3  1.0211   0.93 
PMS-type   1  2.6775   0.97 
PMS-type   2  3.1098   0.94 
PMS-type   3  2.3256   0.55 
Alesse    1  2.2573   0.91 
Alesse    2  5.9769   0.91 
Alesse    3  1.2014   0.71 
Late Follicular   1  2.1588   0.96 
Late Follicular   2  2.7053   0.89 
Late Follicular   3  2.1253   0.73 
Late Luteal   1  1.2275   0.9 
Late Luteal   2  3.9629   0.9 
Late Luteal   3  0.96528  0.84 
R2 > .5 
Comparisons between the two frequencies showed steeper fitted slopes with the 0.5 
Hz overall (across the menstrual phase condition compared to the 1.0-Hz condition).  For 
the 0.5-Hz condition, the PMS-type and Alesse™ user groups decayed earlier as 
evidenced by the analysis of the slopes in which the control group did not provide a 
reasonable fit until the third limb (see Figure 14 and Table 7 for slope references to the 
limbs) while the other groups decayed within the first declining limb.  These results 
suggest that it took longer for the control group to reach decay asymptote.  
Fitted decay functions to percent accuracy amplitude declines averaged across 
menstrual cycle phase showed trends at the 0.5 Hz condition as well. The fitted decays 
for both the LF and LL phases started at roughly the same time; however, the LF data 
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stayed closer to the extrapolated trajectory even when their amplitude was on decline 
compared to the LL phase (see limbs 3 in Figures 17 and 18 and in Table 7).   
Table 7 
          
Percent Amplitude Accuracy decay with respect to the Theoretical Extrapolated Target 
Position for the 0.5 Hz condition.  NOTE: The number of limbs indicates the number of 
times the participants kept from reaching 0% accuracy with each rebounding 
extrapolated trajectory. R2 values less than 0.4 were not used in defining decay slopes. 
See text for details. 
 
 Group              Limb     Slope        R2  
Control   3  2.1213   0.872 
PMS-type   1  2.9943   0.865 
PMS-type   3  1.7284   0.974 
Alesse    1  2.6507   0.887 
Alesse    3  2.2171   0.566 
Late Follicular   1  1.2077   0.913 
Late Follicular   3  2.7799   0.878 
Late Luteal   1  0.95145  0.53  
Late Luteal   3  1.3191   0.8717 
Late Luteal   4  2.3387   0.60753 
R2 > .5 
      
 At the 1.0 Hz frequency the control group did not show decay until the second 
rebound (i.e., decay function fits were viable only the second and third limb (see Figure 
14 and Table 8).  The control group continued to decay at the end of 2 seconds (never 
reaching 0%) whereas the PMS-type group was moving into higher percentages of 
accuracy during the latter portion of the 2 seconds suggesting that they were initially 
distracted by the abrupt offset of the stimulus but later began to look for the stimulus 
where it would have been if it had not been terminated.  
 Comparisons between the two menstrual cycle phases at 1.0 Hz showed that there 
were steeper decays in the first limb during the LL compared to the LF phase.  





Percent Amplitude Accuracy decay with respect to the theoretical Extrapolated Target 
Position for the 1.0 Hz condition. Details as in Table 7. 
  
    Group              Limb     Slope        R2  
Control   2  3.4751   0.94 
Control   3  0.73281  0.63 
PMS-type   1  1.5752   0.8 
PMS-type   2  2.9355   0.9 
Alesse    1  2.7346   0.93 
Alesse    2  3.3555   0.74 
Alesse    3  0.8936   0.74 
Late Follicular   1  2.7688   0.96 
Late Follicular   2  3.0975   0.91 
Late Luteal   1  0.90064  0.71 
Late Luteal   2  3.5753   0.85 
R2 > .5 
Discussion 
 
For the salivary assays for estradiol there was a group main effect where the PMS-
type was significantly different from the Alesse™ user group.   There was a significant 
change in estradiol across the menstrual cycle phases for the control group.  The results 
for progesterone revealed a menstrual cycle phase effect in which progesterone 
concentrations were higher during the LL phase compared to the LF phase.  Pairwise 
comparisons for group by menstrual cycle phase revealed significant differences between 
the control and PMS-type groups between the LF and LL phases. The control group as 
well as the PMS-type group had higher progesterone concentration levels during the LL 
compared to the LF menstrual cycle phase.  The Alesse™ user group did not show 
progesterone concentration differences between menstrual cycle phases.  
For eye movement position (real target amplitude) there was a group main effect 
where the control group had lower overall amplitudes compared to the PMS-type and 
Alesse™ user groups.  There was also a group by frequency interaction that revealed a 
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left-to-right eye movement bias for the PMS-type and Alesse™ users groups, but not the 
control group.  For lead and lag there was an overall lag for all frequencies and the group 
main effect was approaching significance wherein the PMS-type and Alesse™ user 
groups had more eye movement lag compared to the control group.  For persistence time 
after target termination (extrapolated trajectory) the participants had longer durations of 
persistence at 0.25 Hz, and the PMS-type group showed significantly less persistence 
duration than the control group.  Finally, when assessing the amplitude decline of eye 
movements it was found that there were steeper slopes at 0.5 Hz, the PMS-type and 
Alesse™ user groups decayed earlier than the control group, and at 1.0 Hz there were 
steeper slopes during the LL compared to the LF menstrual cycle phase in the first limb.  
 We did not find menstrual cycle phase effects outside of the salivary assays; 
however our group findings suggest that there is something characteristic about the 
groups that is non-humoral that is showing SPEM functioning effects.  This could be a 
result of neurological differences between the groups.  The pattern of cycling and non-
cycling hormones may be a manifestation of these neural circuits.  Therefore, all of our 
interpretations of the results, with the exception of the salivary assays could be related to 
CNS estradiol rather than ovarian peripheral hormone cycles related to LF and LL.  
While some of the effects we observed were expected (i.e., frequency main effects) 
many of our results require further replication.  For example, SPEM persistence duration 
differentiated the control group from the PMS-type group at the 1.0 Hz frequency in 
which the control group persisted for longer durations than the PMS-type group.  This 
was not the case for the Alesse™ users, pointing to CNS estradiol mediation in the length 
of persistence duration.  Although this PMS-type behaviour may seem contradictory at 
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first with respect to many of the perseveration-type symptoms characteristic of depressed 
groups, it may also be consistent with PMS-type symptoms in that disruptions in 
attention and concentration may have been amplified by the abrupt action of target 
termination. 
Salivary Assay for Estradiol and Progesterone 
 The salivary assay results (see page 54) are an integral part of our findings as we 
expanded on the previous study by Richards (2011) and discovered group differences in 
which the control group, but not the PMS-type and Alesse™ users, showed significantly 
higher estradiol concentrations across menstrual cycle phases; however for progesterone 
both the control and PMS-type groups showed significant shifts where progesterone 
concentrations were highest during the LL phase compared to the LF phase.  For 
progesterone, the results did not show significant concentration differences between the 
menstrual cycle phases.  The latter finding should be expected given the consistent 
dosage across the cycle and the inhibition of ovulation which stops the luteal phase from 
occurring.  Further, the control group showed shifts in estradiol and progesterone 
between menstrual phases; however the PMS-type and Alesse™ user groups showed 
stability for estradiol.  For progesterone, the control and PMS-type groups, but not the 
Alesse™ user group, showed significant shifts across menstrual phases. These findings 
suggest that estradiol may be the modulating agent (possibly with progesterone as a 
secondary influence) for the behavioral findings, a point that highlights horizontal SPEM 
neural circuitry and its susceptibility to estradiol influences (see Figure 5). If estradiol 
inhibits GABA, which in turn inhibits omnipause neurons responsible for inhibiting 
excitatory saccadic-burst neurons (Krauzlis, 2005), then elevated CNS estradiol levels 
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should lead to increased saccades, which would diminish the integrity of SPEM.  
Real Target Data  
Directional Bias in Position.  Our real target results were an extended replication 
of Richards (2011) results.  Not only did the control group positionally demonstrate less 
percent lag to target, but the average position results also provided insight into the pattern 
of eye movement differences across the groups.  The control group had lower amplitudes 
in 10 averaged cycles compared to the other groups.  This means that the control group 
stayed closer to the center of the test screen whereas the PMS-type and Alesse™ user 
participants showed greater excursion values.  The frequency by group interaction effect 
for amplitudes demonstrated that, at least with the 0.5 Hz trials, the Alesse™ users had 
the highest excursions, but there was a directional difference in that the control group had 
overall negative average amplitudes whereas the PMS-type group and the Alesse™ users 
had overall positive average amplitudes.  These results support findings from an earlier 
analysis from a separate block of data that also assessed real target amplitudes in sets of 
10 repeating cycles over more frequencies where the results did show greater overall 
excursions in the positive direction for the PMS-types (Wesner, et al., 2014).  Ultimately, 
the PMS-type and Alesse™ user groups had overall average positive excursions.  This 
means that their eye-movements were biased from left-to-right and the control group did 
not show this bias.  The left-to-right SPEM bias may be due to group-related 
dysregulated CNS estradiol.  For example, CNS estradiol-mediated cerebellar 
modifications may modulate activity of the FEF known for its involvement with steady 
left-to-right SPEM (e.g., Swenson, 2006).  Our findings, therefore, suggest that 
ipsiversive SPEM might be modulated by estradiol at the FEF, which would have 
Running head: SPEM AND ESTRADIOL 
 
68 
modulatory effects throughout other oculomotor neural circuits such as the cerebro-
cerebellar circuits.  All of these group differences support our hypothesis that SPEM 
would vary based on hormonal group.  
With respect to the research on schizophrenia (see page 67; Mahlberg, Steinacher, 
Mackert, & Flechtner, 2001; Robinson, 1975), along with depression (Posner et al., 2004), 
and the results of the present study, one might argue that our findings are supportive of 
specific oculomotor pathways being involved in SPEM functioning (see Figure 5).  The 
effects exerted on several oculomotor pathways are different depending on the hormonal 
patterns of the groups. Progesterone itself has been found to decrease saccadic eye 
velocity (van Broekhoven, Backstrom, & Verkes, 2006).  As previously discussed, 
progesterone systems enhance GABAergic systems. The findings that the PMS-type  (see 
page 57) and Alesse™ user groups had greater real-target amplitude excursions from the 
center position and a directional bias demonstrates two possible lines of SPEM deficits 
with respect to latency and direction. Similar to PMS and PMDD, the neurobiology of 
SPEM in bipolar I is a vaguely researched area; however, Martin et al., (2011), using 
functional magnetic resonance imaging, recently discovered that bipolar disordered 
individuals (compared to controls) had increased cerebellar vermis activity during a 
SPEM task where they followed a white horizontally moving target at a velocity of 16.7º 
per second.  As already mentioned, the cerebellar vermis is a known area involved in 
horizontal SPEM; however, the finding from the Martin et al. study suggests a similar 
rhombencephalic pathway to SPEM for affective disorders including PMS and PMDD.  
The cerebellar vermis is involved in the maintenance of SPEM (i.e., persistence, 
amplitude position, lead and leg) as well as regulating saccades, and if it is more active in 
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individuals with PMS-type symptoms, like the effect found for participants with bipolar 
disorder, then this could help explain the group by menstrual phase and frequency effects 
found in the present study. 
Lower Lag in Controls Versus PMS-Types and Alesse™ Users.  For lead and 
lag, there were overall lag patterns found across the groups for all of the frequencies.  As 
to be expected, when the target was fastest (1.0 Hz) there was less lag compared to 0.25- 
and 0.5-Hz conditions as shown in Figure 20. Although there were no significant 
interactions found for menstrual cycle phase or group there was a trend found within the 
groups.  The control group did not lag behind the target to the same degree as the PMS-
type and Alesse™ user groups (p = 0.070).  This suggests that SPEM efficiency is 
enhanced (i.e., is more “on target”) in the normal free-cycling control group compared to 
the more hormonally-stable groups (i.e., Alesse and PMS-type).  As previously noted, 
estradiol inhibits GABAA, and GABA inhibits omnipause neurons which inhibit 
excitatory burst neurons that are known to elicit saccades. CNS estradiol’s indirect 
effects on saccades could explain why the control group was more “on target” compared 
to the PMS-type and Alesse™ user groups. Given that saccades disrupt SPEM and that 
estradiol may be responsible for the inhibition of the mechanism responsible for initiating 
saccades, the stability of estradiol in the PMS-type and Alesse™ user groups may explain 
why they were not as “on target” compared to the control group because a lack of change 
in estradiol concentration across the menstrual cycle may be caused by modulation 
related to affective disorders such as PMS and PMDD.  




Extrapolated Trajectory Data 
Shorter Durations of Persistence for PMS-type and Alesse™ users.  The main 
effect found for frequency where the persistence duration was longest at 0.25 compared 
to 0.5 and 1.0 Hz is most likely attributable to the fact that the eye movements take the 
longest amount of time to get to either the extreme left (-13˚) or extreme right (13˚) 
following stimulus termination during the 0.25 Hz trial.  This means that the eye 
movements took longer to change direction, which would have made it easier for the eye 
movements to stay “on track”. Our other findings are not as simply interpreted, however.  
Increased saccadic eye-movements countermand SPEM and they might explain the 
shorter durations of persistence for the PMS-type group relative to the controls.  As 
previously noted (see pages 5 and 22), affective symptoms such as PMS are also related 
to the attention-startle-response phenomenon.  Kaviani and colleagues (2004) found that 
their participants who had depression were more distracted by a startling stimulus as 
evidenced by their expression of psychomotor slowing and it took the depressives longer 
to dissociate from it. Such findings may explain our measured persistence time 
differences where the control group persisted longer than the PMS-type group at 1.0 Hz 
[as well as the trends in our decay slopes (see page 62) in which the PMS-type group had 
limbs that fit decays earlier than the control group].  The decreased persistence duration 
present in the PMS-type group relative to the control group may have occurred at 1.0 Hz 
rather than 0.25 or 0.5 Hz because it would not take as long to get to an extreme position 
(-13˚ or 13˚) where the persistence would be most likely to end because the eye 
movements have to change direction. Therefore, the distractibility in the PMS-type group 
may have been exacerbated by the change in target direction that occurs earlier in the 1.0 
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Hz compared to the slower target movements with the 0.25- and 0.5-Hz conditions. 
Research has found that schizophrenics, have higher levels of peak velocity of 
saccadic eye movements that seems to be regulated by the saccadic-excitatory burst 
neurons in the brainstem (Mahlberg, Steinacher, Mackert, & Flechtner, 2001; Robinson, 
1975).  Once again, the PMS-type group may have displayed CNS estradiol modulated 
inhibition of the neural circuitry involved in the inhibition of saccades that caused 
elevated saccadic intrusion which then would have lead to less persistence immediately 
following target offset, much like the oculomotor behaviour observed in the 
schizophrenic group in the Mahlberg and colleagues study. Given that drugs that inhibit 
GABA are used to treat schizophrenia symptoms along with the research that 
demonstrates eye movement dysfunctions in this group. Majewska and colleagues (1986) 
pointed out that inhibitory effects of GABAA were potentiated in cultured rat 
hippocampus, and this effect was mediated by higher levels of luteal progesterone.  
Further, Backstrom et al. (2011), based on their investigation of progesterone during the 
luteal phase of the menstrual cycle, found enhanced sensitivity to GABAergic substrates 
have been found during the LL phase in women with PMDD. If the GABAergic system 
is affected during the LL phase, and if saccadic eye movements are interrupted in people 
with schizophrenia due to changes in GABA, then similar eye movement changes may be 
found in people with PMS-type symptoms, which are marked by progesterone 
dysregulation. Progesterone seems to enhance inhibition, and given that SPEM is in fact 
regulated by inhibition and that PMDD symptoms have been associated with the above 
finding, the next logical step is to investigate the progesterone affinity to key receptors 
involved in SPEM circuitry. As already mentioned, estradiol and progesterone are 
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antagonistic to one another during the menstrual cycle in that progesterone seems to 
mitigate the inhibitory effects of estradiol. Therefore, CNS estradiol systems in PMS-
types (like the Alesse™ users) may be causing the menstrual cycle stability found in 
ovarian estradiol, which may have an indirect effect that causes estradiol’s inhibitory 
effects to be mitigated, thereby enhancing inhibitory systems. Our group differences 
support this logic because the control group (which has shifts in estradiol between 
menstrual phases) persisted longer than the hormonally stable PMS-type group.  The 
hormonal stability may be a product of something characteristic about the PMS-type (as 
well as the Alesse™ users) that is not actually causing estradiol to inhibit GABAA 
ultimately leading to more saccadic intrusions and shorter persistence durations. CNS 
estradiol differences between the groups may have such effects on saccades. 
Amplitude decline of eye movements. One of our interesting findings from the 
decay slopes is that while the PMS-type group dissociated faster than the control group 
(possibly related to the attention-startle-response; see page 60), the accuracy of the PMS-
type groups’ eye movements did increase toward the end of the two-second recordings 
even though the rebound limbs were removed.  If the rebound limbs were not removed 
then we could postulate that the eyes were static at center position and the extrapolated 
trajectory rebounds would have created an artificially inflated accuracy; however, the fact 
that the rebound limbs were removed suggests that the PMS-type group continued to 
follow the extrapolated trajectory and did not aymptote to 0 percent. Therefore, although 
the PMS-type group did not persist as long as the control group, they may have had 
higher accuracy of eye movements near the end of the two seconds, suggesting that the 
PMS-type group is more easily distracted by the termination of a stimulus, however their 
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eye-movements continued to move in the fashion of the sinusoid. Estradiol has been 
found to inhibit GABA which is responsible for inhibiting omnipause neurons which then 
inhibit excitatory burst neurons that go on to elicit saccades. Changes in CNS estradiol 
between groups could, therefore, indirectly impact the excitatory burst neurons ability to 
elicit saccades.  If the PMS-type group has characteristic estradiol compared to the 
control group then such neurological differences may cause less saccades in the control 
group causing them to have longer durations of persistence.  
Overall, the findings from the present study suggest that there estradiol seems to 
exhert its effects on the neural circuitry involved in SPEM.  Again, such findings 
(especially with our salivary assay results) implicates estradiol stability as the common 
factor with the possibly of progesterone as secondary antagonistic operator, in horizontal 
SPEM functioning.  
Limitations and Further Directions 
 There were several limitations to the present study.  Firstly, the number of eligible 
participants was limited due to our exclusion of males as well as women taking oral 
contraception other than Alesse™ and Avianne™.  Not only was the participant pool 
restricted, several data files collected for the different frequency trials had to be 
eliminated from the study due to calibration issues with the eye-tracker.   
Also, based on our short persistence durations, it probably would have been beneficial to 
use an eye-tracker with a resolution greater than 60 Hz to better observe the subtle 
variations that may have occurred within the msec time frame of persistence.  Another 
limitation includes the fact that the target termination was not completely randomized 
and, in effect, the termination points for 0.5 and 1.0 Hz began only at 0 degrees or 180 
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degrees.  Therefore, the persistence data from these frequencies all began at the center of 
the screen.  This is potentially confounding as subjects could develop a spatial 
expectation regarding where their stimulus may terminate during their second session. 
Having said this, however, it turned out that these serendipitous center screen offsets 
proved to be beneficial when it came to normalizing the relative time stamps for the 
percent amplitude decay functions; otherwise a secondary confound would have 
developed based on velocity changes at peak and trough excursions. 
For future research, one could include measurement of the saccades rather than 
filtering them out.  As discussed several times throughout this paper, saccades include a 
high velocity gaze shift toward the target in order to focus the target on the fovea.  
Perhaps a future direction could be to focus on the nature of the saccades within SPEM to 
investigate the maintenance and regulation between menstrual cycle phase and group. 
Also, while our intention was to discover any potential effects of estradiol in SPEM, we 
discovered cyclic patterns of progesterone in our salivary assays where progesterone was 
elevated during the LF phase in the PMS-type as well as the control group.   
Our salivary assay results showed a heightened and cyclic presence of progesterone 
in the PMS-type and control participants, but not the Alesse™ users (which is expected 
of the Alesse™-user group because oral contraceptive suppress hormones across the 
cycle.  Estradiol was not cyclic in the PMS-type women whereas it was in the controls.  
Due to the latter, as well as the fact that elevated levels of progesterone during the LL 
menstrual cycle phase is characteristic of PMS-type symptoms, the metabolic interaction 
of estradiol and progesterone might be important for understanding the differences in 
SPEM functioning found in women with PMS-type symptoms. Efforts should be made to 
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replicate these findings to better understand the hormonal modulation of SPEM across 
the menstrual cycle.  One means to further investigate this research could be to include a 
group of women receiving hormone replacement therapy as several oculomotor 
dysfunctions have been associated with the latter (see Baum, 2005; Eisner, Toomey, 
Incognito, O’Malley, & Samples, 2006b; Joffe, Hennen, Soares, Carleson, & Cohen, 
2002).  Also, given that testosterone is aromatized into estradiol, the presence of 
testosterone throughout the cerebellum and brainstem should be further investigated. 
Overall, the present study has garnered several findings that provide further insight into 
estradiol influences on SPEM and these findings point to several avenues of future 
research to further understand potential affective and neurobiological mediation of SPEM.  
 






American Psychiatric Association (2013). Diagnostic and statistical manual of mental  
 disorders (5th ed. ). Washington, DC: Author. 
Andreescu, C. E., Bogdan, A. M., Haasdijk, E. D., Kramer, P., De Jong, F. H., Krust, A.,  
 
 De Zeeuq, C. I., & De Jeu, M. T. (2007).  Estradiol improved cerebellar  
 
 memory formation by activating estrogen receptor β.  The Journal of  
 
 Neuroscience, 27(4), 10832-10839. doi:10.1523/JNEUROSCI.2588-07.2007 
 
Bach, M. (1996).  The Freiburg visual acuity test-automatic measurement of visual  
 




Bach, M. (2007).  The Frieburg Visual Acuity Test-Variability unchanged by post-hoc 
  




Backstrom, T., Haage, D., Lofgren, M., Johansson, I.M., Stromber, J., et al. (2011).   
  
 Paradoxical effects of GABA-A modulators may explain sex steroid induced  
 
 negative mood symptoms in some persons.  Neuroscience, 191, 46-54.  doi:  
 
 10.1016/j.neuroscience.2011.03.061 
Baum, M. (2005).  Adjuvent endocrine therapy in postmenopausal women with early  
 
 breast cancer: Where are we now? European Journal of Cancer, 41, 1667-1667,  
 
 doi: 10.1016/j.ejca.2005.05.006 
 
Beck, A. T., Epstein, N., Brown, G. & Steer, R. A. (1988). An inventory for measuring 
 
clinical anxiety: Psychometric properties. Journal of Consulting and Clinical 
 
Psychology, 56, 893-897. doi: 10.1037/0022-006X.56.6.893 
Running head: SPEM AND ESTRADIOL 
 
77 
Beck, A. T., & Steer, R. A. (1990). Beck Anxiety Inventory manual. New York: The  
Psychological Corporation Harcourt Brace Jovanovich Inc. 
Biegon, A. et al. (2010). Unique distribution of aromatase in the human brain: in vivo  
 studies with PET and [N-methyl-11C]vorozole. Synapse 64, 801–807. 
Boyden, E. S. & Raymond, J. L. (2003). Active reversal of motor memories reveals 
 rules governing memory encoding. Neuron, 39:1031–1042. doi:10.1016/S0896- 
 6273(03)00562-2 
Cordoba Montoya, D. A., & Carrer, H. F. (1997). Estrogen facilitates induction of long  
 term potentiation in the hippocampus of awake rats. Brain Research, 778, 430 – 
 438. 
Donaghy, C., Pinnock, R., Abrahams, S., Cardwell, C., Hardiman, O., Patterson, V.,  
 McGinern, C. R., & Gibson, J. M. (2009).  Ocular fixation instabilities in motor  
 neuron disease: A marker of frontal lobe dysfunction?  Journal of Neurology,  
 256, 420-426. doi:10.1007/s00415-009-0109-x 
Eisner, A., Austin, D. F., & Samples, J., R. (2004).  Short wavelength automated  
 
 perimetry and tamoxifen use.  British Journal of Ophthalmology, 88, 125-130.  
 
Eisner, A., Burke, S. N., & Toomey, M., D. (2004). Visual sensitivity across the  
 




Eisner, A., Incognito, L. J., Toomey, M. D., O’Malley, J. P., & Samples, J. P. (2005).   
  
 Tamoxifen induced optic-nerve-head swelling.  Investigative Ophthalmology and  
 
 Vision Science (ARVO abstract # 2547).  
 




Eisner, A., O’Malley, J. P., Incognio, L. J., & Toomey, M. D. (2006a).  Small optic cup  
 
 sizes among women using tamoxifen: Assessment with scanning laser  
 




Eisner, A., Samples, J. R., Campbell, H. M., & Cioffi, G. A. (1995).  Foveal adaptation  
 




Eisner, A., Toomey, M. D., Falardeau, J., Samples, J. R., & Vetto, J. T. (2007).   
 
 Differental effects of breast cancer survivors. Breast Cancer Research and  
 
 Treatment, 106(2):161-70.  
 
Eisner, A., Toomey, M. D., Incognito, L. J., O’Malley, J. P., & Samples, J. R. (2006b).  
  
Contrasting blue-on-yellow with white-on-white visual fields: roles of visual  
 
adaptation for healthy peri-or postmenopausal women younger than 70 years of  
 
age. Investigative Ophthalmology & Vision Science, 47(12), 5605-5614.  
 
Eisner, A. (1993).  Longitudinal changes of visual function over 18 months: evaluation of  
 
 eyes with high-and low-risk macular degeneration characteristics.  Documenta 
 
 Ophthalmologica Proceedings Series, 56, 175-187.  
 
Flechtner, K. M., Steinacher, B., Sauer, R., & Mackert, A. (1997). Smooth pursuit eye  
 




Frick K. M., Fernandez S. M., & Bulinski S. C. (2002). Estrogen replacement improves  
 spatial reference memory and increases hippocampal synaptophy-sin in aged  
 female mice. Neuroscience, 115, 547–558. 
Running head: SPEM AND ESTRADIOL 
 
79 
Fukushima, K. (2003).  Roles of the cerebellum in pursuit-vestibular interactions.  
  
 The Cerebellum, 2, 223-232. doi:10.1080/14734220310016178 
 
Gyenes, A., Hoyk, Z., Csakvari, E., Siklos, L., & Parducz, A.  (2010).  17β-estradiol  
 attenuates injury-induced microglia activation in the oculomotor nucleus.   
 Neuroscience, 171(3), 677-682. doi:10.1016/j.neuroscience.2010.09.033  
Gorin, M. B., Day, R., Costantino, J. P., Fisher, B., Redmond, C. K., Wickerham, L.,  
 
 Gomolin, J. E., Margolese, R. G., Mathen, M. K., Bowman, D. M., Kaufman, D.  
 
 I., Dimitrov, N. V., Singerman, L. J., Bornstein, R., & Wolmark, N. (1998).   
 
 Long-term tamoxifen citrate use and potential ocular toxicity.  American Journal  
 
 of Ophthalmology, 125, 493-501.  
 
Gupta, P. D., Johar, K., Napgal, M. S., & Vasavada, A. R. (2005).  Sex hormone  
 




Hakim, O. M., Gaber El-Hag, Y., & Maher, H. (2008). Persistence of eye movement  
 following disinsertion of extraocular muscle. Journal of AAPOS, 12(1), 62-65.   
Hansel, C, Linden, D. J., & D’Angelo, E. (2001). Beyond parallel fiber LTD: the  
 diversity of synaptic and non-synaptic plasticity in the cerebellum. Natural  
 Neuroscience, 4, 467– 475. 
Hadjimarkou, M. M., Benham, R., Schwarz, J. M., Holder, M. K., & Mong, J. A. (2008).   
 
 Estradiol suppresses rapid eye movement sleep and activation of sleep-active  
 
 neurons in the ventrolateral pre-optic area.  European Journal of Neuroscience,  
 





Running head: SPEM AND ESTRADIOL 
 
80 
Hakosaka, O., & Wurtz, R. H.  (1985).  Modification of saccadic eye movements by  
 GABA-related substances. I. Effect of muscimol and bibubulline in money  
 superior colliculus.  Journal of Neurphysiology, 52(1), 266-291.  
Hamilton, M. (1960). A rating scale for depression. Journal of Neurology, Neurosurgery  
 and Psychiatry, 23(1), 56-62. 
Hartlage, S. A., Arduino, K. E., & Gehlert, S. (2001). Premenstrual dysphoric disorder  
 and risk for major depressive disorder: A preliminary study. Journal of Clinical  
 Psychology, 57(12), 1571-1578.   
Haselton, M. G., & Gangestad, S. W. (2006).  Conditional expression of women’s desires  
 and men’s mate guarding across the ovulatory cycle.  Hormones and Behavior,  
 49, 509-518. doi:10.1016/j.yhbeh.2005.10.006 
Haug, B. A., Kolle, R. U., Trenkwalder, C., Oertel, W. H., & Paulus, W. (1995).  
 
 Predominant affection of the blue cone pathway in Parkinson's disease. Brain,  
 
 118, 771-778.   
 
Hedges, V. L., Ebner, T. J., Meisel, R. L. & Mermelstein, P. G. (2012).  The cerebellum  
 
 as a target for estrogen action. Frontiers in Neuroendocrinology, 33, 403-411.  
 
 doi: 10.1016/j.frne.2012.08.005 
 
Heron, G., Adams, A. J., Husted, R. (1988).  Central visual fields for short wavelength  
 
 sensitive pathways in glaucoma and ocular hypertension.  Investigative  
 
 Opthalmology & Visual Science, 29(1), 64-72. 
 
Howell, A. (2005).  New developments in the treatment of postmenopausal breast cancer.   
 






Running head: SPEM AND ESTRADIOL 
 
81 
Hu, M. (2014, March 31). What does it mean to have a low R-squared? A warning about  
 






Hu, M., Watson, C.J., Kennedy, R.T., & Becker, J. B.  (2006).  Estradiol attenuates the  
 




Ilg U. J. & Thier, P. (2008).  The neural basis of smooth pursuit eye movements in the  
 rhesus monkey brain.  Brain and Cognition, 68, 229-240.  
 doi:10.1016/j.bandc.2008.08.014 
Inaba, N., Shinomoto, S., Yamane, S., Takemura, A., & Kawano, K. (2007).  MST  
 neurons code for visual motion in space independent of pursuit eye  
 movements.  Journal of Neurophysiology, 97, 3473-3483.  
 doi: 10.1152/jn.01054.2006 
Jarrett, C. B., & Barnes, G. (2002).  Volitional scaling of anticipatory ocular pursuit  
 velocity using precues.  Brain Research Cognitive Brain Research, 14, 383-388.   
 doi:10.1016/S0926-6410(02)00140-4 
Jöchle, W. (1973). Coitus induced ovulation. Contraception, 7(6), 523564. 
 
Joffe, H., Hennen, J., Soares, C. N., Carlson, K., & Cohen, L. (2002).  Hot flashes  
 associated with depression in perimenopausal women seeking primary care.  
 Menopause, 9(6), 392-398.  
Running head: SPEM AND ESTRADIOL 
 
82 
Kaja S., Yang, S. H., Wei, J., Fujitani, K., Liu, R., Brun-Zinkernagel, A. M.,  
 Simkins, J. W., Inokuchi, K., & Koulen, P. (2003).  Estrogen protects the  
 inner retina fron apoptosis and ischema-induced loss of Vesl-1L/Homer 1c  
 immunoreactive synaptic connections.  Investigative Opthalmology & Visual  
 Science, 44, 3155-3162. 
Kanayama, R., Nakamura, T., Sano, R., Ohki, M., Okuyama, T., Kimura, Y., et al.  
 
 (1994). Effect of aging on smooth pursuit eye movement. Acta Otolaryngology 
 
 (Stockh), Suppl 511, 131-134. 
 
Kathmann, N., Hochrein, A., Uwer, R., & Bondy, B.  (2003).  Deficits in gain of smooth  
 pursuit eye movements in schizophrenia and affective disorder patients and  
 their unaffected relatives. American Journal of Psychiatry, 160, 696-702.   
Kaviani, H., Gray, J. A., Checkley, S. A., Raven, P. W., Wilson, G. D.,  & Kumari, V.  
  
 (2004).  Affective modulation of the startle response in depression: influence of  
 
 the severity of depression, anhedonia, and anxiety.  Journal of Affective  
 Disorders, 83, 21-31. doi:10.1016/j.jad.2004.04.007 
Kawakami, M., & Ohno, S. (1981).  Estrogen-sensitive neurons with preoptic projections  
 in the lower brain stem of the female rat.  Endocrinology Journal, 28(5), 677-684. 
Khakpay, R., Semnanian, S., Java, M., & Janahmadi, M. (2010).  The effect of inta-locus  
  
 coeruleus injection of 17β-estradiol on inflammatory pain modulation in male rat.   
 
 Behavioural Brain Research, 214(2), 409-416. doi:10.1016/j.bbr.2010.06.012 
 
Koorengevel, K.M., Beersma, D.G., Den Boer, J.A., & Van Den Hoofdakker, R.H.  
 (2002).  Sleep in seasonal affective disorder patients in forced desynchrony: an  
 explorative study.  Journal of Sleep Research, 11(4), 347-356.  Retrieved from  
 http://www.ncbi.nlm.nih.gov/pubmed/12464103  
 
Running head: SPEM AND ESTRADIOL 
 
83 
Krauzlis, R. J., & Lisberger, S. G. (1989).  A control systems model of smooth pursuit  
 eye movements with realistic emergent properties. Neural Computation, 1,  
 116-122.  
Krauzlis, R.J. (2005).  The control of voluntary eye movements: New Perspectives.   
 The Neuroscientist, 11(2), 124-137. 
Lam, R. W., Beattie, C. W., Buchanan, A., Remick, R. A., & Zis, A. P. (1991). Low  
 
 electrooculographic ratios in patients with seasonal affective disorder. American  
 
 Journal of Psychiatry, 148(11), 1526-1529.  
 
Leuner B., Mendolia-Loffredo S., & Shors T. J. (2004). High levels of estrogen enhance  
 associative memory formation in ovariectomized females.  
 Psychoneuroendocrinology, 29, 883– 890. doi:10.1016/j/psyneuen.2003.08.001 
Lisberger, S. G., Morris, E. J., & Tychsen, L. (1987).  Visual motion processing and  
 sensory-motor integration for smooth pursuit eye movements.  Annual Review  
 of Neuroscience, 10, 97-129. doi:10.1146/annurev.ne.10.030187.000525 
Lisberger, S. G., & Movshon, J. A. (1999).  Visual motion analysis for pursuit eye  
 
 movements in area mt of macaque monkeys.  The Journal of Neuroscience,  
 
 19, 2224-2246.  
 
Majewska, M. D., Harrison, N. L., Schwartz, R. D., Barker, J. L., & Paul, S. M. (1986).   
 
 Steroid hormone metabolites are barbiturate-like modulators of the GABA  
 
 receptor.  Science 232, 1004-1007. 
 
Mahlberg, R., Steinacher, B., Mackert, A., & Flechtner, K. M. (2001). Basic parameters  
 
 of saccadic eye movements – differences between unmedicated schizophrenia and  
 
 affective disorder patients. European Archives of Psychiatry and Clinical  
 
 Neuroscience, 251, 205–210. 
Running head: SPEM AND ESTRADIOL 
 
84 
 Manns, I. D., Mainville, L., & Jones, B. E. (2001). Evidence for glutamate, in addition to 
acetylcholine and GABA, neurotransmitter synthesis in basal forebrain neurons 
projecting to entorhinal cortex. Neuroscience, 107(2), 249-263. 
Martin, L. F., Olincy, A., Ross, R. G., Du, Y. P., Singel, D., Shatti, S., & Tregellas, J. R. 
(2011).  Journal of Psychiatric Research, 45; 670-677.  
McEwen, B. S., & Milner, T. A. (2007).  Hippocampal formation: shedding light on the  




McEwen, B. S. (2001).  Invited review: estrogens effects on the brain: Multiple sites and  
  
 molecular mechanisms. Journal of Applied Physiology, 91(6), 2785-801.  
 
Medina, J. F., & Lisberger, S. G. (2007).  Variation, signal, and noise in cerebellar  
 
 sensory-motor processing for smooth-pursuit eye movements.  The Journal of  
 
 Neuroscience, 27, 6832-6842.  doi:10.1523/JNEUROSCI.1323-07.2007 
 
Missal, M., & Keller, E. L. (2002). Common inhibitory mechanism for saccades and  
  
 smooth-pursuit eye movements. Journal of Neurophysiology, 88, 1880-1892. 
 
Miura, K., Kobayashi, Y., & Kawano, K. (2009). Ocular responses to brief motion of  
 
 textured backgrounds during smooth pursuit in humans. Journal of  
 
 Neurophysiology, 102, 1736-1747. 
 
Moos, R. H. (1968). The development of a menstrual distress questionnaire.   
 Psychosomatic Medicine, 30, 853-867. Retrieved from:  
 http://www.psychosomaticmedicine.org/content/30/6/853.full.pdf+html 
Munaut, C., Lambert, V., Noel, A., Frankenne, F., Deprez, M., Foidart, J.M., Rakic, J.M.  
  
 (2001).  Presence of oestrogen receptor type beta in human retina. British Journal  
 
 of Ophthalmology, 85, 877-882. doi:10.1136/bjo.85.7.877  




Noriega, N. C., Eghlidi, D. H., Garyfallou, V. T., Kohama, S. G., Kryger, S. G., &  
 
 Urbanski, H. K.  (2010).  Influence of 17 β-estradiol and progesterone on  
 
 GABAergic gene expression in the arcuate nucleus, amygdala and hippocampus  
 
 of the rhesus macaque.  Brain Research, 1307, 28-42.   
 
Nyberg, S., Wahlstrom, G., Backstrom, T., & Poromaa, I. G.  (2004). Altered sensitivity  
 
 to alcohol in the late luteal phase among patients with premenstrual dysphoric  
 




Ogueta, S. B., Schwartz, S. D., Yamashita, C. K., & Farber, D. B. (1999).  Estrogen  
 
 receptor in the human eye: Influence of gender and age on gene expression.   
 
 Investigative Ophthalmology & Vision Science, 40, 1906-1911.  
 
Ono, S., & Mustari, M. J. (2008).  Smooth Pursuit-Related Information Processing in  
 Frontal Eye Field Neurons That Project to the NRTP.  Cerebral Cortex, 19, 1186- 
 1197.  doi:10.1093/cercor/bhn166 
O’Hara, M. W., & Rehm, L. P. (1983).  Hamilton Rating Scale for Depression: reliability  
 
and validity in judgments of novice raters. Journal of Consulting and Clinical  
 
Psychology, 51(2), 318-319. 
 
Ozaki, N., Rosenthal, N. E., Myers, F., Schwartz, P. J., & Oren, D. A. (1995). Effects of  
 
 season on electro-oculographic ratio in winter seasonal affective disorder.  
 
 Psychiatry Research, 59, 151-155.  
 
Pacheco-Cutillas, M. & Edgar, F. D.  (1999).  Acquired colour vision defects in  
 
 glaucoma—their detection and clinical significance. British Journal of 
 
 Optholmology,83, 1396-1402.  doi:10.1136/bjo.83.12.1396 




Pack, C. C., & Born, R. T. (2001).  Temporal Dynamics of a Neural Solution to the  
 
 Aperture Problem in Visual Area MT of Macaque Brain.  Nature, 409, 1040- 
 
 1042. doi:10.1038/35059085 
 
Palagini, L., Baglioni, C., Ciapparelli, A., Gemignani, A., & Riemann, D. (2013).  REM  
 
 sleep dysregulation in depression: State of the art.  Sleep Medicine Reviews.   
 
 Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/23391633 
 
Pardo, J. V., Pardo, P. J., Humes, S. W., & M, I. P. (2006). Neurocognitive dysfunction  
 
 in antidepressant-free, non-elderly patients with unipolar depression: alerting and  
  
 covert orienting of visuospatial attention. Journal of Affective Disorders, 92(1),  
 
 71-78.  
 
Parry, B., L., Cover, H., Mostofi, N., LeVeau, B., Sependa, P. A., Resnick, A., & Gillin,  
 
 C. (1995).  Early vesus late partial sleep deprivation in patients with premenstrual  
 
 dysphoric disorder and normal comparison subjects.  The American Journal of  
 
 Psychiatry, 152(3), 404-412. doi:10.1016.j.psychres.2007.11.017 
 
Parry, B. L., Hauger, R., LeVeau, B., Mostofi, N., Cover, H., Clopton, J., & Gillin, C.   
 
 (1996).  Circadian rhythms of prolactin and thyroid-stimulating hormone during  
 
 the menstrual cycle and early versus late sleep deprivation in premenstrual  
 
 dysphoric disorder.  Psychiatry Research, 62, 147-160.  
 
Pearlstein, R. & Steiner, M. (2008).  Premenstraul dysphoric disorder: burden of illness  
 








Pillsworth, E. G., Haselton, M. G., & Buss., D. M. (2004) Ovulatory shifts in female 
  




Posner, M. I., Walker, J. A., Friedrich, F. J., Rafal, R. D. (1984).  Effects of parietal 
 
 injury on covert orienting of attention.  Journal of Neuroscience 4, 1863-1874. 
 
Raffi, M., Squatrito, S., & Maioli, M. G. (2007).  Gaze and Smooth Pursuit Signals  
 
 Interact in Parietal Area 7m of the Behaving Monkey. Experimental Brain  
 
 Research, 182, 35-46. doi:10.1007/s00221-007-0967-3 
 
Rapkin, A. J. 1999. Progesterone, GABA and mood disorder in women. Archives of  
 Women’s Mental Health, 2, 97–105. doi:101007/s007370050041 
Rapkin, A.J., McDonald, M., & Winer, S. A. (2007).  Ethinyl estradiol/drospirenone for  
  
 the treatment of the emotional and physical symptoms of premenstrual dysphoric  
 
 disorder. Women’s Health, 3(4), 395-408.  doi:10.2217/17455057.3.4.395 
 
Reed, S. C., Levin, F. R., & Evans, S. M. (2008). Changes in mood, cognitive  
  
 performance and appetite in the late luteal and follicular phases of menstrual  
 
 cycle in women with and without PMDD (premenstrual dysphoric disorder).   
 
 Hormones and Behaviour, 54, 185-193. doi: 10.1016/j/yhbeh.2008.02.018. 
 
Rewal, M., Jung, M.E., Wen, Y., Brun-Zinkernagel, A.M., & Simpkins, J.W.  (2003).   
 
 Role of the GABAA system in behavioral, motoric, and cerebellar protection by  
  
estrogen during ethanol withdrawal.  Alcohol, 31, 49-61. 
 
Rhodes, M. E., & Frye, C. A. (2004).  Estrogen has mnemonic-enhancing effects in the  
 




Running head: SPEM AND ESTRADIOL 
 
88 
Richards, M. A. (2011). Visual and Hormonal Indicators of Premenstrual Dysphoric 
 Disorder (PMDD). (Unpublished doctoral dissertation). Lakehead University, 
 Thunder Bay, ON.).   
Robinson, D.A. (1975). Oculomotor control signals.  In: Bach-y-Rita P, Lennerstrand G 
 (eds) Basic Mechanisms of Ocular Motility and Their Clinical Implications.  
 Pergamon, Oxford, pp 337-374. 
Robinson, F. R., & Fuchs, A. F. (2001).  The Role of the Cerebellum in Voluntary Eye  
 
 Movements.  Annual Review of Neuroscience, 24, 981-1004. 
 
Rosenthal, N. E., Sack, D. A., Gillin, J. C., Lewy, A. J., Goodwyn, F. K., Davenport, P.  
 S. et al. (1984). Seasonal affective disorder. A description of the syndrome and  
 estradiol, visual functioning, and pms 218 preliminary findings  
 with light therapy. Archives of General Psychiatry, 41(1), 72-80. Retrieved from: 
 http://blog.ecu.edu/sites/penderst/files/2011/01/SAD-original-Rosenthal- 
 report.pdf 
Rottach, K. G., Zivotofsku, A. Z., Das, V. E., Averbuch-Heller, L., Discenna, A. O.,  
 Poonyathalang, A., & Leigh, R. J. (1996).  Comparison of horizontal, vertical and  
 diagonal smooth pursuit eye movements in normal human subjects. Vision  
 Research, 36(14), 2189-2195. 
Scarduzio, M., Panichi, R., Pettorossi, V. E. & Grassi, S. (2013).  Synaptic Long-Term 
 Potentiation and Depression in the Rat Medial Vestibular Nuclei Depend on 
 Neural Activation of Estrogenic and Androgenic Signals. PLOS ONE, 8(11), 
 1-10. 




Schlack, A., Hoffmann, K. P., & Bremmer, F. (2003).  Selectivity of macaque ventral  
 
 intraparietal area (area VIP) for Smooth Pursuit Eye Movements.  Journal of  
 
 Physiology, 551, 551-561. doi:10.1113/jphysiol.2003.042994 
 
Seggie, J., MacMillan, H., Griffith, L., Shannon, H. S., Martin, J., Simplson, J., et al.  
 
 (1991). Retinal pigment epithelium response and the use of the EOG and Arden  
 
 ratio in depression. Psychiatry Research, 36, 175-185. 
 
Sharpe, J. A. (2008). Neurophysiology and neuroanatomy of smooth pursuit: Lesion  
 
 studies. Brain and Cognition, 68, 241–254. 
 
Shechter, A., Lesperance, P., Ying Kin, N. M., & Boivin, D. B. (2012).  Nocturnal  
 polysomnographic sleep across the menstrual cycle in premenstrual dysphoric 
 disorder.  Sleep Medicine, 13, 1071-1079. doi:10.1016/j.sleep.2012.05.012 
Shiroma, S., Yamaguchi, T., & Kometani, K. (2005).  Effects of 17beta-estradiol on  
 chemically induced long-term depression.  Neuropharmacology, 49(1), 97-102.   
 doi:10.1084/jem.20102665 
Smith, R. N., Studd, J. W., Zamblera, D., & Holland, E. F. (1995).  A randomized  
 comparison over 8 months of 100 micrograms and 200 micrograms twice weekly  
 doses of transdermal estradiol in the treatment of severe premenstrual syndrome.  
 British Journal of Obstetrics and Gynaecology, 102(6), 475-484.   
Smyrnis, N., Evdokimidis, I., Mantas, A., Kattoulas, E., Stefanis, N., & Constantinidis, 
 T. S. (2007).  Smooth pursuit eye movements in 1,087 men: effects of schizotypy, 
 anxiety, and depression. Experimental Brain Research, 179, 397-404. 
 doi:10.1007/s00221-006-0797-8 




Soares, C. N., Almeida, D. D., Joffe, H., & Cohen, L. S. (2001).  Efficacy of estradiol for  
  
 the treatment of depressive disorders in perimenopausal women: a double-blind,  
 
 randomized, placebo-controlled trial.  Archives of General Psychology, 58, 529- 
 
 534.  
 
Sparks, D. L. (2002).  The brainstem control of saccadic eye movements. Nature Reviews  
 
 Neuroscience, 3, 952-964.  
 
Stuphorn, V., & Schall, J. D.  (2006).  Executive control of countermanding saccades by  
 




Sundström, I., Andersson, A., Nyberg, S., Ashbrook, D., Purdy, R., & Bäckström T.  
 (1998). Patients with premenstrual syndrome have a different sensitivity to a  
 neuroactive steroid during the menstrual cycle compared to control subjects.  
 Neuroendocrinology 67(2), 126–138. doi: 10.1016/S0893133X(97)00086-9 
Sundström, P, Smith, S., & Gulinello, M. (2003). GABA receptors, progesterone, and  
 premenstrual dysphoric disorder. Archive of Women’s Mental Health, 6, 23-41.  
 doi: 10.1007/s00737-002-0147-1 
Swenson, R. D. (2006). Review of Clinical and Functional Neuroscience. Retrieved from  
http://www.dartmouth.edu/~rswenson/NeuroSci/index.html 
Their, P., & Erickson, R. G. (1992).  Responses of Visual-Tracking Neurons from  
 Cortical Area MST To Visual, Eye and Head Motion.  The European Journal of  
 Neuroscience, 4, 539-553.  
Tsutsi, K. (2012).  Neurosteroid Biosynthesis and Action During Cerebellar  
 
 Development.  Cerebellum, 11, 414-415.  doi:10.1007/s12311-011-0341-7 
 
 
Running head: SPEM AND ESTRADIOL 
 
91 
van Broekhoven, F., Backstrom, T., & Verkes, R. J. (2006).  Oral Progesterone  
Decreases Saccadic Eye Velocity and Increases Sedation in Women.  
Psychoneuroendocrinology, 31; 1190-9.  
Velisek, L., & Veliskova, J. (2002).  Estrogen treatment protects GABA(B) inhibition in  
 the dentate gyrus of female rate after kainic acid-induced status epilepticus.  
 Epilepsia, 43(5), 146-151.  
Vouimba, R. M., Foy, M. R., Foy, J. G., & Thompson, R. F. (2000).  17ß-estradiol 
 suppresses expression of long-term depression in aged rats.  Brain Research 
 Bulletin, 53(6), 783-787. 
Wagner, E. J., Ronnekleiv, O. K., Bosch, M. A., & Martin, K. J.  (2001).  Estrogen  
 biphasically modifies hypothalamic GABAergic function concomitantly with 
 negative and positive control luteinizing hormone release.  The Journal of 
 Neuroscience, 21(6), 2085-2093 
Walker, J. E. (1983). Glutamate, GABA, and CNS disease:  A Review. Neurochemical 
Research, 8(4) 521-550. 
Wallace, J. M., Stone, L. S., & Masson, G. S. (2005).  Object motion computation for  
 the initiation of Smooth Pursuit Eye Movements in humans.  Journal of  
 
 Neurophysiology, 93, 2279-2293.  doi:10.1152/jn.01042.2004 
Watson, N. R., Studd, J. W., Savvas, M., Garnett, T., & Baber, R. J.  Treatment of severe  
 premenstrual syndrome with oestradiol patches and cyclical oral norethisterone.   
 Lancet, 2(8665), 730-732. doi:10.1002/14651858 




Wesner, M.F., Currie, E., Richards, M. & Oinonen, K. (2014). Women With 
Premenstrual Syndrome (PMS) Symptoms and Monophasic Contraceptive Users, 
Compared to Non-Symptomatic Controls, Show Asymmetric Horizontal Smooth 
Pursuit Amplitudes During Their Late Luteal Menstrual Phase, Journal of Vision, 
Vision Science Society. 
Wesner, M.F. & Richards, M.A. (2011). Women with PMS show unilateral bias in 
horizontal smooth pursuit eye movements during their late luteal (low estradiol) 
menstrual cycle phase. 41st Annual Meeting of the Society for Neuroscience, 
Washington, DC.  
Wesner, M. F. & Tan, J. (2006). Contrast sensitivity in seasonal and nonseasonal  
depression. Journal of Affective Disorders, 95, 19-28. 
Wichniak, A., Riemann, D., Kiemen, A., Voderholzer, U., & Jernajczyk, W. (2000).  
 
 Comparison between eye movement latency and REM sleep parameters in major  
 




Wickham, L. A., Gao, J., Toda, T, Rocha, E. M., Ono, M., & Sullivan, D. A. (2000). 
 
 Identification of androgen, estrogen and progesterone receptor mRNA’s in the  
 
eye.  Acta Ophthalmologic Scandinavica, 78, 146-153.   







































































































































































Dear Potential Participant, 
Thank you for your interest in our research. We are currently conducting a 
study that is investigating health and visual functioning in women. Individuals who 
participate in this study will receive up to four points toward their credit in the 
Introductory Psychology course. 
Following completion of a screening questionnaire (containing personal 
questions about demographic information, health and reproductive history, emotions 
and personality, caffeine intake, and morning/evening preference) some participants 
will be selected to participate in two approximately one-and-a-half-hour laboratory 
sessions. Dates for laboratory testing will be scheduled based upon the results of a 
simple hormonal test and will involve the collection of a salivary sample, completion 
of a brief questionnaire, and 4 visual tests. These tests are based on standard computer-
based psychophysical procedures. In all visual tests, participants will be presented 
various images on a computer display and will subsequently be asked to make 
judgments based on the appearance of the images. A sub-sample of participants will be 
asked to collect salivary samples at home and return them to the lab the following 
morning. Following completion of the laboratory sessions, all participants will be fully 
debriefed, and provided with a list of project references and resources. 
An extensive history of research has demonstrated that all tasks involved in 
this study constitute minimal risk to participants. If at any time you feel uncomfortable 
with any of the experimental tasks or procedures, or note any negative effects, you are 
free to withdraw your consent at any time. Participants may choose not to answer any 
questions of which they are uncertain or material that cause them discomfort. Early 
termination of the study will not affect the award of bonus points. The benefits that 
you may expect to derive from this study include (a) an appreciation of research on 
health, (b) an opportunity to contribute to scientific research, and (c) course credit (up 
to four bonus points).  
All information collected during the course of this project will be held in strict 
confidence. At no time will any identifying information be divulged to individuals 
outside of the research team. Anonymity and confidentiality will be maintained at all 
times throughout the study and in the dissemination of results for publication and 
appropriate conference presentations. After data is collected there will be no way to 
connect any data with any particular participant. All information will be stored in the 
laboratories of Dr. Wesner and Dr. Oinonen at Lakehead University for a period of at 
least five years. Findings from the projects will be made available to interested 
participants upon completion of the project.  
If you have any questions or concerns regarding the experiment, please do not 
hesitate to contact us directly. I can be reached by phone (807) 252-1412 or through e-
mail (evcurrie@lakeheadu.ca). Dr. Michael Wesner (mwesner@lakeheadu.ca), or 
Lakehead University’s Research Ethics Board at (807) 343-8283. 
Thank you for your interest in the project. Sincerely, 
Emily Currie, Department of Psychology, Lakehead University 
 





 The purpose of the present study, conducted by Emily Currie and Dr. Michael 
Wesner of the Department of Psychology at Lakehead University, is to examine 
health and visual functioning in women. If you are currently enrolled in an 
Introductory Psychology section, one bonus point will be awarded for the completion 
of this screening questionnaire. Information collected from the screening 
questionnaire will be used to select some participants for subsequent laboratory 
sessions. Individuals who are selected for these sessions and who participate further 
in the study will receive an additional one to three bonus points (depending on the 
number of laboratory sessions attended) towards their final mark in Introductory 
Psychology. 
 Your participation in the screening will involve the completion of a 
questionnaire that will take approximately 30-40 minutes. The questionnaire includes 
personal questions designed to collect information on: demographics, reproductive 
history, the menstrual cycle, emotion and personality, caffeine intake, and 
morning/evening preference. You may choose not to respond to any questions that 
cause you discomfort.  
Participation in this study is voluntary and you may withdraw at any time 
without explanation or penalty. Records of your participation will be kept in strict 
confidence. As well, no identifying information will be disclosed in the 
dissemination of the results of this study. As per university requirements, all data will 
be stored for at least five years in research laboratories at Lakehead University and 
remain anonymous and confidential. Individuals who meet specific criteria will be 
asked to participate in subsequent laboratory sessions. Therefore, we have asked for 
your name and telephone number here. Once we have determined who will be asked 
to participate in subsequent sessions, this information will be removed and 
information from your questionnaire will remain both anonymous and confidential. 
The benefits you may expect from the study are (a) an appreciation of research on 
health, (b) an opportunity to contribute to scientific research and (c) course credit (up 
to four bonus points). Throughout the study, participant information will be coded 
using a numbering system. There is no way that your name can be connected to your 
responses. There are no known physical or psychological risks associated with 
participating in this study. If you have any questions or concerns regarding this study 
please contact the principal investigators, Emily Currie (252-1412) or Dr. Michael 














I agree to participate in the present study that is investigating health and visual 
functioning in women. I understand that my participation is entirely voluntary: I may 
withdraw my consent from this experiment at any time, and this act will have no bearing 
on any remuneration I will receive, nor will it have any undesirable consequences. 
The following points have been explained to me:  
1. The purpose of this research is to identify what factors are related to women’s health 
and visual functioning. The benefits I may expect from the study are (a) an 
appreciation of research on health, (b) an opportunity to contribute to scientific 
research and (c) course credit (up to three additional bonus points). 
2. The procedure will be as follows: During a single session, researchers will obtain a 
salivary sample (via the technique of passive drool). Following a brief visual 
screening test, I will then be required to complete a total of four tests of visual 
functioning. These tests of visual functioning will be repeated in a subsequent lab 
session scheduled following the completion of the first lab session. A subset of 
participants will also be given the necessary materials, and asked to collect salivary 
samples at home to be returned to the lab the following day. 
3. There are no known serious risks involved in participating in this study.   
4. All of the data collected as well as my salivary samples will remain strictly 
confidential. My responses will not be associated with my name. Instead, my data 
will be associated with a code number when the researchers store the data. 
5. The experimenter(s) will answer any other questions about the research either now or 
during the course of the experiment (other than specific questions about the 
hypotheses). If I have any other questions or concerns, I can address them to the 
principal experimenter, Emily Currie (evcurrie@lakeheadu.ca) or Dr. M. Wesner 
343-8457 (mwesner@lakeheadu.ca)  
6. Upon completion of my participation, I will receive a more detailed written 
explanation about the rationale underlying this experiment. 
7. I am interested in receiving a summary of the results upon completion of the study:
   
                          yes       no      
 If yes, please indicate your email address: ____________________________ 
I have read and understood the consent form, and I agree to participate in this 
study under these conditions. 
            _____________________________  _____________________________ 
      Participant’s Printed Name    Signature 
 
 
      _____________________________           ______________________________ 
    Date                                       Experimenter Name 
 
 





We appreciate your participation in our study, and thank you for spending your 
time to help us with our research. When you arrived here you were told that the purpose 
of this study was to investigate health and visual functioning in women. One of the 
factors in which we are interested is how hormonal sensitivity may affect perception 
within the visual system.  In order to test this hypothesis, we have selected groups of 
women that the literature suggests are hormonally sensitive. These include women who 
experience symptoms of PMS, as well as women who report a history of experiencing 
oral contraceptive side effects. We also selected women without any of these symptoms. 
Given that this study involves some aspects of which you were not fully informed 
at the outset, it is very important that you not discuss your experiences with other 
students until the end of the term.  If participants have prior knowledge of our specific 
predictions it may influence their results, and the data we collect would be not be reliable. 
Because you will be given a copy of this feedback to take home, please do not make it 
available to other students. If you do not keep this form, please dispose of it rather than 
leaving it somewhere where other students might read it. Please feel free to discuss with 
the experimenter any feelings you have about the study right away. Should you have 
further questions, do not hesitate to contact Emily Currie, Brandi Person, or Dr. Michael 
Wesner, using the information listed below. 
In addition to examining visual functioning, we will also be using your salivary 
samples to obtain a measure of estradiol. We have included three references on the 
following page in case you are interested in doing further reading relating to the study 
topics. 
  We hope that you have enjoyed participating in our study, and thank you very 
much for your assistance. As noted on the consent form, you will receive a summary of 
the results of the study at its completion if you have indicated an interest. 
Principal Investigators: 
Emily Currie    Dr. M. Wesner 
Department of Psychology       Associate Professor 
Lakehead University   Department of Psychology 
955 Oliver Road   Lakehead University 
Thunder Bay, ON, P7B 5E1   955 Oliver Road 
(807) 252-1412    Thunder Bay, ON, P7B 5E1 









Mental Health Resource Sheet 
 
Sometimes people can feel upset when thinking about their mood.  If you feel as 
though you would like to talk to a mental health practitioner for any reason please 
consider the resources listed below: 
 
• Lakehead University Health and Counseling Centre: 343-8361 
 
• Thunder Bay Counseling Centre : 626-1880 
 
• Catholic Family Development Centre: 345-7323 
 
• Thunder Bay Crisis Response (24 hours): 346-8282 
 
• Emergency services are available at the Thunder Bay Health Sciences Centre 
 
 
If you are interested in doing further reading that is related to this study, here are three 
relevant journal articles that you might want to obtain. 
 
 
Oinonen, K., & Mazmanian, D. (2002).  To what extent do oral contraceptives  
Influence mood and affect? Journal of Affective Disorders, 70, 229-240. 
 
Stickgold, R., Whidbee, D., Schirmer, B., Patel, V., & Hobson, J.A. (2000). Visual 
 discrimination task improvement: A multi-step process occurring during sleep. 


























Cycle Phase LL     MF 
 
Are you currently taking Oral or Hormonal Contraceptives YES NO 
 
 
1) This scale consists of a number of words that describe different feelings and emotions.  
Read each item and then mark the appropriate answer in the space next to that word.  
Indicate to what extent you have felt this way today.  Use the following scale to record 
your answers. 
    
  Very Slightly       A little Moderately    Quite a bit     Extremely  
  or not at all (1)          (2)        (3)            (4)  (5) 
 
Interested  1  2  3  4  5 
Distressed  1  2  3  4  5 
Excited  1  2  3  4  5 
Upset   1  2  3  4  5 
Strong   1  2  3  4  5 
Guilty    1  2  3  4  5 
Scared   1  2  3  4  5 
Hostile   1  2  3  4  5 
Enthusiastic  1  2  3  4  5 
Proud   1  2  3  4  5 
Irritable  1  2  3  4  5 
Alert   1  2  3  4  5 
Ashamed  1  2  3  4  5 
Inspired  1  2  3  4  5 
Nervous  1  2  3  4  5 
Determined  1  2  3  4  5 
Attentive  1  2  3  4  5 
Jittery   1  2  3  4  5
   
Active   1  2  3  4  5 
Afraid   1  2  3  4  5 
 
2) The following list shows common symptoms and feelings. For each item, choose the 
descriptive category from the box below that best describes what you have been feeling 
for the past 24 hours. That is, for each item, decide whether you have “no experience of 
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the symptom, ” or whether your experience is “present mild,” “present moderate,”  
“present strong,” or present severe.” Then indicate your response by circling the 
corresponding number. 
 
No experience         Present    Present      Present     Present  
of symptom             Mild        Moderate     Strong      Severe      
  (0)            (1)        (2)         (3)          (4) 
 
Muscle stiffness           0   1         2                3                      4
   
Headaches          0   1         2                3                      4
  
Cramps             0   1         2                3                      4
  
Backache              0   1         2                3                      4
  
Fatigue             0   1         2                3                      4
  
General aches              0   1         2                3                 
and Pains  
Weight gain           0   1         2                3                      4
  
Skin Blemish          0   1         2                3                      4 
or disorder  
 
Painful or tender             0   1         2                3                      4 
breasts  
 
Swelling              0   1         2                3                      4
  
Loneliness          0   1         2          3           4
  
Anxiety          0   1         2                3                      4
  
Mood Swings          0   1         2                3                      4
  
Crying           0   1         2                3                      4
  
Irritability           0   1         2                3                      4
  
Tension           0   1         2                3                      4
   
Feeling sad or           0   1         2                3                      4 
Blue 
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Restlessness          0   1         2                3                      4
  
3) Please rate your current level of physical pain by circling the best answer. 
 
1- none at all  2- mild  3- moderate 4-severe 5-extremely 
severe/debilitating 
 
4) Please rate your current level of discomfort by circling the best answer. 
 
1- none at all  2- mild  3- moderate 4-severe 5-extremely 
severe/debilitating 
 
5) Please rate your level of fatigue by circling the best answer 
 
1- none at all   2- mild  3- moderate 4-severe 5-extremely 
severe/debilitating 
 
6a) Have you consumed any alcohol in the past 24 hours?  YES NO 
 
  b) If yes, please indicate the number of drinks _____ 
 
7a) Have you consumed any caffeine prior to coming to the lab this morning?  YES
  NO 
 
  b) If yes, please indicate the number of servings ______ 
 
8. Have you taken any medication to alleviate symptoms of pain in the past 24 hours 
(Tylenol, Advil, Midol, etc…)   YES  NO 
 
9. How many hours of sleep did you receive last night? ________  
 
10. What time did you wake up this morning? ________ 
 
11. Are you currently menstruating? YES NO 
 
12. If day 1 is the day that you started menstruating, what day of the menstrual cycle are 













































                                              
 
Safety Precautions  
 Liquid stop is a 2-molar solution of sulfuric acid. This solution is caustic; use with care.  
 See ‘Material Safety Information’ at the end of procedure. 
 A safety data sheet is available upon request. 
 
pH Indicator 
A pH indicator in the assay diluent alerts the user to samples with high or low pH values. Acidic samples will turn the 
diluent yellow. Alkaline samples will turn the diluent purple. Dark yellow or purple wells indicate that a pH value for 
that sample should be obtained using pH strips. Progesterone values from samples with a pH < 4.0 or > 9.0 may be 
artificially inflated or lowered. (18) 
Storage  
All components of this kit are stable at 2-8°C until the kit’s expiration date. 
 
Materials Supplied with Single Kit 
Item Quantity/Size 
1 Microtitre Plate 
Coated with rabbit anti-
progesterone antibodies. 
1/96-well 
2 Progesterone Standard 
2430 pg/mL, in a saliva-
like matrix.  
Serially dilute before use 




1 vial/1 mL 
3 Progesterone Controls 
High, Low, in a saliva-
like matrix. Ready to use. 
Contain: progesterone, 
buffer, preservative. 
2 vials/500 µL each 
4 Wash Buffer 
Concentrate (10X) 
Dilute before use 





1 bottle/100 mL 
5 Assay Diluent 
Contains: phosphate 
buffer, pH indicator, 
preservative. 
1 bottle/60 mL 
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6 Progesterone Enzyme 
Conjugate 
Concentrate. Dilute 
before use with assay 
diluent.  
(See step 5 of Procedure.) 
Contains: Progesterone 
conjugated to HRP,  
preservative. 
1 vial/50 µL 
7 TMB Substrate Solution 
Non-toxic, ready to use. 
1 bottle/25 mL 
8 2 M Stop Solution 
Contains: sulfuric acid. 
1 bottle/12.5 mL 
9 Non-Specific Binding 
(NSB) Wells 
Do not contain anti-
progesterone antibody. 
Break  
off and insert as blanks 
(optional) where needed. 
1 strip 
 
Materials Needed But Not Supplied 
 Precision pipette to deliver 22.5 µL, 50 µL, 100 µL, and 200 µL  
 Precision multichannel pipette to deliver 50 µL, 150 µL, and 200 µL 
 Vortex 
 Plate rotator with 0.08-0.17 inch orbit capable of 500 rpm 
 Plate reader with a 450 nm filter 
 Log-linear graph paper or computer software for data reduction 
 Deionized water 
 Reagent reservoirs 
 One disposable polypropylene tube to hold at least 18 mL  
 Small disposable polypropylene tubes  
 Pipette tips and a serological pipette 
 
Limitations 
 Samples with progesterone values greater than 2430 pg/mL should be further diluted with assay diluent and 
rerun for accurate results. To obtain the final progesterone concentration, multiply the concentration of the diluted 
sample by the dilution factor. 
 A pH value should be obtained on samples that appear yellow or purple after assay diluent is added and the 
plate is mixed (Step 6). Samples with pH values < 4.0 or > 9.0 should be recollected. 








 Samples collected with sodium azide are unsuitable for this assay. 
 Any quantitative results indicating abnormal progesterone levels should be followed by additional testing and 
 evaluation.  
 
Specimen Collection 
Avoid sample collection within 60 minutes after eating a major meal or within 12 hours after consuming alcohol. 
Acidic or high sugar foods can compromise assay performance by lowering sample pH and influencing bacterial 
growth. To minimize these factors, rinse mouth thoroughly with water 10 minutes before sample is collected. 
The preferred method for collecting whole saliva is by unstimulated passive drool. Donors may collect whole saliva by 
tilting the head forward, allowing the saliva to pool on the floor of the mouth, and then passing the saliva through the 
Saliva Collection Aid (SCA), Item No. 5016.02, into a polypropylene vial. Collection protocols are available on 
request or online at www.salimetrics.com.  
Do not use Salivettes, the SalivaBio Oral Swab (SOS), Sorbettes, cotton, or polyester materials to collect samples. 
False readings will result. (19)  
Samples visibly contaminated with blood should be recollected. We recommend that samples be screened for possible 
blood contamination (20,21) using a reliable screening tool such as the Salimetrics Blood Contamination EIA Kit (Item 
No. 1-1302/1-1302-5). Do not use dipsticks, which result in false positive values due to salivary enzymes. 
Record the time and date of specimen collection.  
Sample Handling and Preparation 
After collection it is important to keep samples cold, in order to avoid bacterial growth in the specimen. Refrigerate 
sample within 30 minutes, and freeze at or below -20ºC within 4 hours of collection. (Samples may be stored at -20ºC 
or lower for long term storage.)  
Do not add sodium azide to saliva samples as a preservative, as it may cause interference in the immunoassay. 
Freezing saliva samples will precipitate mucins. On day of assay, thaw completely, vortex, and centrifuge at 1500 x g 
(@3000 rpm) for 15 minutes. Centrifuging removes mucins and other particulate matter which may interfere with 
antibody binding, leading to falsely elevated results. Samples should be at room temperature before adding to assay 
plate. Pipette clear sample into appropriate wells. Re-freeze saliva samples as soon as possible after adding to the assay 
plate. Centrifuge/re-centrifuge saliva samples each time that they are thawed. Avoid additional freeze-thaw cycles. 
 
Reagent Preparation 
•Bring all reagents to room temperature and mix before use. A minimum of 1.5 hours is recommended for the 18 mL of 
assay diluent used in Step 5 (conjugate dilution) to come to room temperature. 
•Bring microtitre plate to room temperature before use. Note: It is important to keep the foil pouch with the plate 
strips closed until warmed to room temperature, as humidity may have an effect on the coated wells. 
•Prepare 1X wash buffer by diluting wash buffer concentrate 10-fold with room-temperature deionized water (100 mL 
of 10X wash buffer to 900 mL of deionized water. Dilute only the amount needed for current day’s use, and 
discard any leftover reagent. (If precipitate has formed in the concentrated wash buffer, heat to 40°C for 15 minutes 
to dissolve crystals. Cool to room temperature before use in assay.) 
•Prepare serial dilutions of the progesterone standard as follows: 
◦◦Label five polypropylene microcentrifuge tubes or other small tubes 2 through 6. 
◦◦Pipette 200 µL of assay diluent in tubes 2 through 6. 
◦◦Serially dilute the standard 3X by adding 100 µL of the 2430 pg/mL standard (tube 1) to tube 2. Mix well. After 
changing pipette tips, remove 100 µL from tube 2 to tube 3. Mix well. Continue for tubes 4, 5, and 6. The final 
concentrations of stan-dards for tubes 1 through 6 are, respectively, 2430 pg/mL, 810 pg/mL, 270 pg/mL, 90 pg/mL, 30 




This kit uses break-apart microtitre strips. You may run less than a full plate. Unused wells must be stored at 2-8°C in 
the sealed foil pouch with desiccant and used in the frame provided. 
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•The quantity of reagent provided with this kit is sufficient for three individual runs. The volume of diluent and 
conjugate used for assays using less than a full plate should be scaled down accordingly, keeping the same dilution 
ratio. 
•Do not mix components from different lots of kits. 
•When using a multichannel pipette, reagents should be added to duplicate wells at the same time. Follow the same 
sequence when adding additional reagents so that incubation time with reagents is the same for all wells. 
•To ensure highest quality assay results, pipetting of samples and reagents must be done as quickly as possible (without 
interruption) across the plate. Ideally, the process should be completed within 20 minutes or less. 
•When running multiple plates, or multiple sets of strips, a standard curve must be run with each individual plate and/or 
set of strips. 
•The temperature of the laboratory may affect assays. Salimetrics’ kits have been validated at 68-74ºF (20-23.3ºC). 
Higher or lower temperatures will cause an increase or decrease in OD values, respectively. Salimetrics cannot 
guarantee test results outside of this temperature range. 





General Kit Use Advice  
 This kit uses break-apart microtitre strips. You may run less than a full plate. Unused wells must be stored at 
2-8°C in the sealed foil pouch with desiccant and used in the frame provided. 
 The quantity of reagent provided with this kit is sufficient for three individual runs. The volume of diluent 
and conjugate used for assays using less than a full plate should be scaled down accordingly, keeping the same dilution 
ratio. 
 Do not mix components from different lots of kits. 
 When using a multichannel pipette, reagents should be added to duplicate wells at the same time. Follow the 
same sequence when adding additional reagents so that incubation time with reagents is the same for all wells. 
 To ensure highest quality assay results, pipetting of samples and reagents must be done as quickly as possible 
(without interruption) across the plate. Ideally, the process should be completed within 20 minutes or less. 
 When running multiple plates, or multiple sets of strips, a standard curve must be run with each individual 
plate and/or set of strips.  
 The temperature of the laboratory may affect assays. Salimetrics’ kits have been validated at 68-74ºF (20-
23.3ºC). Higher or lower temperatures will cause an increase or decrease in OD values, respectively. Salimetrics cannot 
guarantee test results outside of this temperature range. 
 Avoid microbial contamination of opened reagents. Salimetrics recommends using opened reagents within 
one month.  




 Routine calibration of pipettes is critical for the best possible assay performance. 
 Use of progesterone-enhanced creams or supplements by the laboratory technician performing the analysis 
can adversely affect results. 
Procedure 
Step 1: Determine your plate layout. Here is a suggested layout. 
1 2 3 4 5 6 7 8 9 10 11 12 
A 2430 Std 2430 Std C-H C-H 
B 810 Std 810 Std C-L C-L 
C 270 Std 270 Std Unk-1 Unk-1 
D 90 Std 90 Std Unk-2 Unk-2 
E 30 Std 30 Std Unk-3 Unk-3 
F 10 Std 10 Std Unk-4 Unk-4 
G Zero Zero Unk-5 Unk-5 
H NSB* NSB* Unk-6 Unk-6  
*NSB = Non-specific binding wells. These may serve as blanks. Use is optional. 
 
Step 2: Keep the desired number of strips in the strip holder and place the remaining strips back in the foil pouch. If 
you choose to place non-specific binding wells in H-1, 2, remove strips 1 and 2 from the strip 
holder. Break off the bottom wells in each strip. Place the strips back into the strip holder leaving H-1, 2 blank. Break 
off 2 NSB wells from 
the strip of NSBs included in the foil pouch. Place in H-1, 2. Alternatively, NSBs may be placed wherever you choose 







Step 3: Pipette 18 mL of assay diluent into the disposable tube. (Scale down proportionally if not using the entire 
plate.) Set aside for Step 5. 
Step 4: 
•Pipette 50 µL of standards, controls, and unknowns into appropriate wells. Standards, controls, and unknowns should 
be assayed in duplicate. 
•Pipette 50 µL of assay diluent into two wells to serve as the zero. 
•Pipette 50 µL of assay diluent into each NSB well. 
Step 5: Dilute the enzyme conjugate 1:800 by adding 22.5 µL of the conjugate to the 18 mL of assay diluent prepared 
in Step 3. (Scale down proportionally if not using the entire plate.) Conjugate tube may be centrifuged for a few 
minutes to bring the liquid down to the tube bottom. If using 6 or fewer strips, 12.5 µL of conjugate to 10 mL of assay 
diluent may be used. Immediately mix the diluted conjugate solution and add 150 µL to each well using a multichannel 
pipette. 
Step 6: Cover plate with adhesive cover provided. Rotate the plate 
continuously at 500 rpm for 1 hr at room temperature. 
Step 7: Wash the plate four times with 1X wash buffer. A plate washer is recommended. However, washing may be 
done by gently squirting wash buffer into each well with a squirt bottle, or by pipetting 300 µL of wash buffer into each 
well and then flipping the liquid into a sink. After each wash, the plate should be thoroughly blotted on paper towels 
before turning upright. If using a plate washer, blotting is still recommended after the last wash. 
Step 8: Add 200 µL of TMB solution to each well with a multichannel pipette. 
Step 9: Mix on a plate rotator for five minutes at 500 rpm and incubate the plate in the dark at room temperature for an 
additional 25 minutes. 
Step 10: Add 50 µL of stop solution with a multichannel pipette. 
Step 11: 
•Mix on a plate rotator for three minutes at 500 rpm. Be sure all wells have turned yellow. If green color remains, 
continue mixing until green color turns to yellow. 
Caution: Spillage may occur if mixing speed exceeds 600 rpm. 
•Wipe off bottom of plate with a water-moistened, lint-free cloth and wipe dry. 
•Read in a plate reader at 450 nm. Read plate within 10 minutes of adding stop solution. (Correction at 490 to 630 nm 
is desirable.) 





Figure 1. Hormones as a function of the menstrual cycle phases.  Cyclic patterns of the 
follicle stimulating hormone (blue), the luteinizing hormone (red), estradiol (purple) and 
progesterone (green) are depicted.  Figure obtained from: 
http://embryology.med.unsw.edu.au/Science/ANAT2341lecture03.htm   
 






Figure 2. This figure depicts the screen that is used to set up the FrACT and explains the 
stimulus-response task.  Landoldt ‘C’s (on the right) were displayed at 8 orientations with 
response keys mapped out to indicate where the observers perceived the opening of the 
‘C’. We used this display to explain to the participant that individual ‘C’s would be 
presented one-at-a-time and that the participant would have to individuate (using the 
number pad on the keyboard) where the opening of the ‘C’ was oriented. Figure obtained 
from Bach, 2007. 








Figure 4.  Horizontal, sinusoidal target amplitudes labeled as either degrees sine phase 
position (top row), or as degrees visual angle with respect to the screen (bottom row) in 
which negative defines leftward movement and positive defines rightward movement. 
The timing of these excursions is dependent on the temporal frequency (0.25, 0.5, 1.0 
cycles/sec or Hz) of the oscillating spot target. 
 








Figure 5.  Neural circuitry involved in horizontal SPEM throughout the cerebral cortex, 
cortex, cerebellum, and brainstem.  This overview is used to understand the underlying 
neural circuits where estradiol receptors have been found and/or where estradiol has 
putatively had effects on the maintenance and regulation of SPEM.  




Figure 6. Enzyme-linked immunosorbent assay (ELISA).  Estradiol (red) and 
progesterone (blue) concentrations (± 1 SD) taken during the Late Follicular (right) and 
Late Luteal (left) phases of the participant’s menstrual cycle.  Note PMS-type and 
Alesse™ users show no significant estradiol concentration changes across the cycle.  In 
addition, Alesse™ users also show no progesterone shifts, which is to be expected based 
on the synthetic analogue effects on receptor sensitivities. Based on concentration, PMS-
types appear to have the highest overall levels of estradiol of the three groups and the 
highest concentration of progesterone during LL phase.  Of more interest, however, is in 
the temporal patterns: PMS and Alesse™ users have comparable stable estradiol levels, 
controls and PMS have comparable cycling progesterone levels, and Alesse™ users have 



























































































































































































Figure 7. Enzyme-linked immunosorbent assay (ELISA).  Estradiol (light colours) and 
progesterone (dark colours) concentrations (± 1 SD) taken during the Late Follicular 
(left) and Late Luteal (right) phases of the participant’s menstrual cycle.  Results as seen 
in Figure 6. 
 
 




Figure 8. The extrapolated trajectory following real target offset with amplitude (degrees 
visual angle) as a function of time (sec).  When the stimulus was terminated (red arrow) 
the real target eye movements (black) eye movements ended and the duration and 
accuracy of persistence was measured by comparing the participant’s actual eye 
movements to where there eye movements would have been if the stimulus was still 
present (the blue extrapolated trajectory).  If the participants eye movements exceeded 
the 2- sided 95% confidence interval range derived from their real target eye movements 
(highlighted by the light blue shading) then that deviation marked the completion of a 
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Figure 10.  Fitted am
plitude data and deltas as a function of tim
e from
 
offset and relative tim
e, respectively, for a participant from
 the PM
S-
type group during a 0.5 H
z frequency trial.  D
etails as in Figure 9 for 
extrapolated trajectory and m
enstrual phase.  
 







Figure 11.  Fitted am
plitude data and deltas as a function of tim
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offset and relative tim




user group during a 0.5 H
z frequency trial. D
etails as in Fig.ure 9 for 
extrapolated trajectory and m
enstrual phase.    




Figure 12. Sinusoidal cycle phase amplitude (position on the screen) ranging from -13° 
to 13° as a function of relative time (sec) for 0.5 Hz where the target was terminated at 
either 0° or 180° phase position. The sinusoid is partitioned by 0.125 second limbs to 
indicate what limbs of the sinusoid were used for further analysis (in red) and what were 
removed to avoid rebound effects. See text for further description of “rebounds”. 




Figure 13. Same as Figure 12 except for a 1.0-Hz target.  Limbs are separated by 0.25 
second to indicate decay (in red) and rebound (in black) intervals. 
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b as illustrated in Figures 12 and 13  (presented as 
an icon in the bottom
 right). 
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Figure 19.  Mean average eye position on the eye tracker test collapsed across menstrual 
cycle phase with respect to real target measured in degrees visual angle as a function of 
frequency for the control (blue), PMS-type (purple), and Alesse™ users (green) groups 
(± 1 SEM). Note the group difference between the controls and Alesse™ users with 
Alesse™ users showing greater real-target excursions as well as the group by frequency 
interaction between the Alesse™ users and controls at 0.5 Hz.  Unfortunately, there were 
no menstrual cycle phase main effects (see text for more details).  




Figure 20. Percent lead averaged across group and menstrual phase based on lead 
count/total count of lead and lag • 100 as a function of frequency (± 1 SEM). Note the 
main effect of frequency where the 1.0 Hz condition revealed significantly less lead than 
the 0.5 or 1.0 Hz frequencies. 




Figure 21.  Percent of lead versus lag averaged across menstrual phase based on lead 
count/total count of lead and lag • 100 as a function of group (± 1 SEM). Note there was a 
trend for a main effect where the control group lagged the target less than the PMS-type 
and Alesse™ users. 
 




Figure 22.  Mean persistence duration (in seconds) after target termination as a function 
of target frequency (in Hz) collapsed across group (± 1 SEM). Note the main effect of 
frequency where the 0.25 Hz condition produced significantly longer persistence than the 
0.5 or 1.0 Hz oscillating frequencies. 




Figure 23.  Mean persistence time measured in seconds with Persistence Duration after 
Target Offset plotted as a function of Frequency (± 1 SEM).  Duration was defined by 
95% confidence intervals within real target tracking position (see text for details). 
Control (blue), PMS-type (purple), and Alesse™ (green) represent the mean persistence 
durations for the groups. Note the differences between frequencies as well as the 
interaction effect between the control and PMS-type groups at 1.0 Hz. Unfortunately 
there were no menstrual cycle phase main effects. 
 
